Document:

<Page>

                                                                    EXHIBIT 10.6

          CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.

VER. 9/9/02                                               EXECUTION COPY
                                                          TLO:  KES/LN

                      MASSACHUSETTS INSTITUTE OF TECHNOLOGY

                                       AND

                          MOMENTA PHARMACEUTICALS, INC.

                       EXCLUSIVE PATENT LICENSE AGREEMENT

        M.I.T.'s offer of this agreement is open until November 15, 2002

<Page>

                                TABLE OF CONTENTS

<Table>
<S>                                                                     <C>
TABLE OF CONTENTS.......................................................ii
R E C I T A L S.........................................................1
1. Definitions..........................................................2
2. Grant of Rights......................................................6
3. COMPANY Diligence Obligations........................................8
4. Royalties and Payment Terms..........................................10
5. Reports and Records..................................................11
6. Patent Prosecution...................................................13
7. Infringement.........................................................14
8. Indemnification and Insurance........................................17
9. No Representations or Warranties.....................................19
10. Assignment..........................................................19
11. General Compliance with Laws........................................19
12. Termination.........................................................21
13. Dispute Resolution..................................................21
14. Miscellaneous.......................................................23
APPENDIX A..............................................................26
APPENDIX B..............................................................28
APPENDIX C..............................................................29
APPENDIX D..............................................................32
</Table>

                                       ii
<Page>

VER. 9/9/02

                      MASSACHUSETTS INSTITUTE OF TECHNOLOGY
                       EXCLUSIVE PATENT LICENSE AGREEMENT

     This Agreement, effective as of the date set forth above the signatures of
the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute
of Technology ("M.I.T."), a Massachusetts corporation, with a principal office
at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Momenta
Pharmaceuticals, Inc. ("COMPANY"), a Delaware corporation, with a principal
place of business at 43 Moulton Street, Cambridge, MA 02138.

                                 R E C I T A L S

     WHEREAS, M.I.T. is the owner or a joint owner of certain PATENT RIGHTS (as
later defined herein) relating to:

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     M.I.T. CASE NO. [**];

     and has the right to grant licenses under its interest in said PATENT
RIGHTS;

<Page>

     WHEREAS, M.I.T. is the sole owner of the PATENT RIGHTS for M.I.T. Case Nos.
[**].

     WHEREAS, M.I.T. and the [**] jointly own the PATENT RIGHTS for M.I.T. Case
[**] and have signed a joint invention agreement that appoints the M.I.T.
Technology Licensing Office as the sole and exclusive agent for licensing such
PATENT RIGHTS;

     WHEREAS, M.I.T. and the [**] jointly own the PATENT RIGHTS for M.I.T. Case
No. [**] and M.I.T. has contacted [**] for its authorization to act as its agent
for the purposes of licensing [**] rights in the intellectual property of M.I.T.
Case No. [**] in return for a share in royalties;

     WHEREAS, M.I.T. desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license
thereunder;

     WHEREAS, COMPANY has represented to M.I.T., to induce M.I.T. to enter into
this Agreement, that COMPANY shall commit itself to a thorough, vigorous and
diligent program of exploiting the PATENT RIGHTS so that public utilization
shall result therefrom; and

     WHEREAS, COMPANY desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

     NOW, THEREFORE, M.I.T. and COMPANY hereby agree as follows:

                                 1. DEFINITIONS.

     1.1 "AFFILIATE" shall mean any legal entity (such as a corporation,
partnership, or limited liability company) that is controlled by COMPANY. For
the purposes of this definition, the term "control" means (i) beneficial
ownership of at least fifty percent (50%) of the voting securities of a
corporation or other business organization with voting securities or (ii) a
fifty percent (50%) or greater interest in the net assets or profits of a
partnership or other business organization without voting securities.

     1.2 "EXCLUSIVE PERIOD" shall mean the period of time set forth in Section
2.2.

     1.3 "FAIR MARKET VALUE" of a share of Common Stock or other security of the
COMPANY (a "SECURITY") shall be the highest price per share that the COMPANY
could

                                        2
<Page>

reasonably be expected to obtain from a willing buyer (not a current employee or
director) for shares of such SECURITY sold by the COMPANY, from authorized but
unissued shares, as determined in good faith by the Board of Directors of the
COMPANY, unless the COMPANY shall become subject to a merger, acquisition or
other consolidation pursuant to which the COMPANY is not the surviving party, in
which case the current fair market value of a share of such SECURITY shall be
deemed to be the value received by the holders of the such SECURITY for each
share of such SECURITY pursuant to the COMPANY's acquisition.

     1.4 "FIELD SEQUENCING MACHINES" shall mean the commercial sale or leasing
of sequencing machines, including the performance of sequencing services, but
only to the extent such sequencing services are (a) required for the seller or
lessor of such a sequencing machine to develop or manufacture such sequencing
machine; or (b) performed by the purchaser of such a sequencing machine using
the sequencing machine. The development, performance and provision of sequencing
services apart from the development, manufacture or use of a commercially sold
sequencing machine are not included within this field.

     1.5 "INDEPENDENT THIRD PARTY" shall mean any third party other than M.I.T.,
COMPANY, an AFFILIATE, or a SUBLICENSEE.

     1.6 "IMPROVEMENT" shall mean any patentable invention, or group of
patentable inventions so linked as to form a single general inventive concept
(as general inventive concept is described in Rule 13 of the Regulations under
the Patent Cooperation Treaty), disclosed to the M.I.T. Technology Licensing
Office, made under M.I.T. research programs in which either Professor [**] or
Professor [**] is the principal investigator, on or before December 31, 2004,
and which are dominated by the claims of the PATENT RIGHTS SEQUENCING for which
exclusive rights are granted in Section 2.2.

     1.7 "LICENSED PRODUCT" shall mean any sequencing machine that, in whole or
in partabsent the license granted hereunder, when used would infringe one or
more claims of the PATENT RIGHTS.

     1.8 "MILESTONE PAYMENTS" shall mean a payment to COMPANY or AFFILIATE from
a SUBLICENSEE due upon achievement of an agreed upon technical, business, or
regulatory milestone pertaining to the research, development or
commercialization of LICENSED PRODUCTS. Illustrative examples of such milestones
include, but are not limited to: delivery of a sample LICENSED PRODUCT
customized to the requirements of the SUBLICENSEE and obtaining regulatory
approval for a LICENSED PRODUCT. Payments

                                        3
<Page>

received by COMPANY for the purchase or sale of equity in COMPANY at a price up
to and including the FAIR MARKET VALUE are excluded from this definition. The
amount of such payment which exceeds the FAIR MARKET VALUE is included in this
definition. Bona fide RESEARCH SUPPORT PAYMENTS are excluded from this
definition. Bona fide payments to COMPANY or AFFILIATES from a SUBLICENSEE for
rights other than those licensed hereunder are excluded from this definition.

     1.9 "NET SALES" shall mean, the gross amount billed by COMPANY and its
AFFILIATES and SUBLICENSEES for LICENSED PRODUCTS, less the following:
          (i) customary trade, quantity, or cash discounts to the extent
actually allowed and taken;
          (ii) amounts repaid or credited by reason of rejection or return;
          (iii) to the extent separately stated on purchase orders, invoices, or
other documents of sale, any taxes or other governmental charges levied on the
production, sale, transportation, delivery, or use of a LICENSED PRODUCT which
is paid by or on behalf of COMPANY; and
          (iv) outbound transportation costs prepaid or allowed and costs of
insurance in transit.

          No deductions shall be made for commissions paid to individuals
whether they be with independent sales agencies or regularly employed by COMPANY
and on its payroll, or for cost of collections. NET SALES shall occur on the
earlier of receipt of payment or ninety (90) days after the date of billing for
a LICENSED PRODUCT. If a LICENSED PRODUCT is distributed at a discounted price
that is substantially lower than the customary price charged by COMPANY, or
distributed for non-cash consideration (whether or not at a discount), NET SALES
shall be calculated based on the non-discounted amount of the LICENSED PRODUCT
charged to an independent third party during the same REPORTING PERIOD or, in
the absence of such sales, on the fair market value of the LICENSED PRODUCT.
Sales or other transfers between or among COMPANY and any of its AFFILIATES for
the purpose of subsequent resale to third parties shall not be included in the
calculation of NET SALES. In the event of a sale or transfer between the COMPANY
and one of its SUBLICENSEES for the purpose of subsequent resale to third
parties, the subsequent resales to third parties shall not be included in the
calculation of NET SALES.

     1.10 "PATENT RIGHTS" shall mean:

                                        4
<Page>

          (a) the United States and international patents listed on APPENDIX A,
B AND C;
          (b) the United States and international patent applications and/or
provisional applications listed on APPENDIX A, B, AND C and the resulting
patents;
          (c) any patent applications resulting from the provisional
applications listed on APPENDIX A, B, AND C, and any divisionals, continuations,
continuation-in-part applications, and continued prosecution applications (and
their relevant international equivalents) of the patent applications listed on
APPENDIX A, B, AND C and of such patent applications that result from the
provisional applications listed on APPENDIX A, B, AND C, to the extent the
claims are directed to subject matter specifically described in the patent
applications listed on APPENDIX A, B, AND C, and the resulting patents;
          (d) any patents resulting from reissues, reexaminations, or extensions
(and their relevant international equivalents) of the patents described in (a),
(b), and (c) above; and
          (e) international (non-United States) patent applications and
provisional applications filed after the EFFECTIVE DATE and the relevant
international equivalents to divisionals, continuations, continuation-in-part
applications and continued prosecution applications of the patent applications
to the extent the claims are directed to subject matter specifically described
in the patents or patent applications referred to in (a), (b), (c), and (d)
above, and the resulting patents.

     1.11 "PATENT RIGHTS HEPARINASE" shall mean the PATENT RIGHTS listed on
APPENDIX A.

     1.12 "PATENT RIGHTS MASSPEC" shall mean the PATENT RIGHTS listed on
APPENDIX B.

     1.13 "PATENT RIGHTS SEQUENCING" shall mean the PATENT RIGHTS listed on
APPENDIX C.

     1.14 "REPORTING PERIOD" shall begin on the first day of each calendar
quarter and end on the last day of such calendar quarter.

     1.15 RESEARCH SUPPORT PAYMENTS" shall mean payments to COMPANY or AFFILIATE
from a SUBLICENSEE that are expressly intended only to fund or pay for
equipment, supplies, employees, full time consultants, research, products,
services or expenses incurred or to be incurred on behalf of that SUBLICENSEE.

                                        5
<Page>

     1.16 "SUBLICENSE INCOME" shall mean any payments that COMPANY or an
AFFILIATE receives from a SUBLICENSEE in consideration of a sublicense of the
rights granted COMPANY and AFFILIATES under Section 2.1, including without
limitation license fees, license maintenance fees, and other payments, but
specifically excluding MILESTONE PAYMENTS and royalties on NET SALES. Payments
received by COMPANY for the purchase or sale of equity in COMPANY at a price up
to and including the FAIR MARKET VALUE are excluded from this definition. The
amount of such payment which exceeds the FAIR MARKET VALUE is included in this
definition. Bona fide RESEARCH SUPPORT PAYMENTS are excluded from this
definition. Bona fide payments to COMPANY or AFFILIATES from a SUBLICENSEE for
rights other than those granted under Section 2.1 are excluded from this
definition.

     1.17 "SUBLICENSEE" shall mean any non-AFFILIATE sublicensee of the rights
granted COMPANY under Section 2.1.

     1.18 "TERM" shall mean the term of this Agreement, which shall commence on
the EFFECTIVE DATE and shall remain in effect until the expiration or
abandonment of all issued patents and filed patent applications within the
PATENT RIGHTS, unless earlier terminated in accordance with the provisions of
this Agreement.

     1.19 "TERRITORY" shall mean worldwide.

                               2. GRANT OF RIGHTS.

     2.1 LICENSE GRANTS. Subject to the terms of this Agreement, M.I.T. hereby
grants to COMPANY and its AFFILIATES for the TERM a royalty-bearing license
under M.I.T.'s rights in the PATENT RIGHTS HEPARINASE, the PATENT RIGHTS
MASSPEC, and the PATENT RIGHTS SEQUENCING to develop, make, have made, use,
sell, offer to sell, lease, and import LICENSED PRODUCTS in the FIELD SEQUENCING
MACHINES in the TERRITORY.

     2.2 EXCLUSIVITY. In order to establish an exclusive period for COMPANY,
M.I.T. agrees that it shall not grant any other license for M.I.T.'s rights in
the PATENT RIGHTS HEPARINASE and in the PATENT RIGHTS SEQUENCING to make, have
made, use, sell, lease and import LICENSED PRODUCTS in the FIELD SEQUENCING
MACHINES in the TERRITORY unless sooner terminated as provided in this
Agreement.

                                        6
<Page>

     In addition, subject only to the terms of any sponsorship agreement under
which an IMPROVEMENT invention was made, M.I.T. hereby grants to COMPANY a first
option to add IMPROVEMENTS to the PATENT RIGHTS, only in the fields for which
exclusive rights are granted in Section 2.2, for six months after COMPANY has
been notified of the existence of each such IMPROVEMENT. Within one month after
the M.I.T. Technology Licensing Office receives disclosure of any IMPROVEMENT,
and to the extent that the IMPROVEMENT is available for licensing under the
terms of any sponsorship agreement, M.I.T shall notify COMPANY in writing of
such IMPROVEMENT, furnishing COMPANY a copy of the invention disclosure and any
related patent applications. COMPANY may exercise its right to add such
IMPROVEMENT to the PATENT RIGHTS within six months after receipt of M.I.T's
notice by so notifying M.I.T. in writing and paying M.I.T. a fee of [**] Dollars
($[**]) per invention disclosure covering IMPROVEMENTS. Upon COMPANY's exercise
of such right, the Appendix of this Agreement that describes the PATENT RIGHTS
that dominate the IMPROVEMENT shall be deemed to have been amended to add the
invention disclosure (and any related patent applications) covering such
IMPROVEMENT, and such IMPROVEMENT and any resulting patent applications and
patents shall thereafter be included in PATENT RIGHTS for all purposes of this
Agreement, without any additional fee, other than the [**] Dollar fee referred
to in the previous sentence, and M.I.T. shall provide COMPANY with an updated
APPENDIX A OR C for its records

     2.3 SUBLICENSES. COMPANY shall have the right to grant sublicenses of its
rights under Section 2.1. COMPANY shall incorporate terms and conditions into
its sublicense agreements sufficient to enable COMPANY to comply with this
Agreement. COMPANY shall promptly furnish M.I.T. with a fully signed photocopy
of any sublicense agreement. Upon termination of this Agreement for any reason,
any SUBLICENSEE not then in default shall have the right to seek a license from
M.I.T., at M.I.T.'s own discretion.

     2.4 U.S. MANUFACTURING. COMPANY agrees that any LICENSED PRODUCTS used or
sold in the United States will be manufactured substantially in the United
States.

     2.5 RETAINED RIGHTS.

          (a)   M.I.T. M.I.T. retains the right to practice under the PATENT
RIGHTS for research, teaching, and educational purposes.

          (b)   FEDERAL GOVERNMENT. COMPANY acknowledges that the U.S. federal
government retains a royalty-free, non-exclusive, non-transferable license to
practice any

                                        7
<Page>

government-funded invention claimed in any PATENT RIGHTS as set forth in 35
U.S.C. Sections 201-211, and the regulations promulgated thereunder, as amended,
or any successor statutes or regulations.

     2.6 NO ADDITIONAL RIGHTS. Nothing in this Agreement shall be construed to
confer any rights upon COMPANY by implication, estoppel, or otherwise as to any
technology or patent rights of M.I.T. or any other entity other than the PATENT
RIGHTS, regardless of whether such technology or patent rights shall be dominant
or subordinate to any PATENT RIGHTS.

                        3. COMPANY DILIGENCE OBLIGATIONS.

     3.1 DILIGENCE REQUIREMENTS. COMPANY shall use diligent efforts, or shall
cause its AFFILIATES and SUBLICENSEES to use diligent efforts, to develop
LICENSED PRODUCTS and to introduce LICENSED PRODUCTS into the commercial market;
thereafter, COMPANY or its AFFILIATES or SUBLICENSEES shall make LICENSED
PRODUCTS reasonably available to the public.

     3.2 [**] AND RESULTANT DILIGENCE REQUIREMENTS. If, at any time after the
second anniversary of the EFFECTIVE DATE, MIT receives [**] the PATENT RIGHTS in
the [**], M.I.T. shall furnish COMPANY with [**]. COMPANY shall indicate to MIT
[**] the development and sale of LICENSED PRODUCTS under the PATENT RIGHTS.
Thereupon, [**], COMPANY must meet the following diligence requirements:

          (a)   Within ninety (90) days after M.I.T.'s [**], COMPANY shall
furnish, or shall cause its AFFILIATES or SUBLICENSEES to furnish, M.I.T.
with a written research and development plan describing the major tasks to be
achieved in order to bring to market a LICENSED PRODUCT specifying the number
of staff and other resources to be devoted to such commercialization effort.

          (b)   Within sixty (60) days after the end of each calendar year,
COMPANY shall furnish, or shall cause its AFFILIATES or SUBLICENSEES to furnish,
M.I.T. with a written report (consistent with Section 5.1(a)) on the progress of
its efforts during the immediately preceding calendar year to develop and
commercialize LICENSED PRODUCTS. The report shall also contain a discussion of
intended efforts and sales projections for the year in which the report is
submitted.

          (c)   COMPANY shall permit an in-plant inspection by M.I.T. on or
before the second anniversary of the date of notification by M.I.T. [**], and
thereafter permit in-plant

                                        8
<Page>

inspections by M.I.T. at regular intervals with at least twelve (12) months
between each such inspection.

          (d)   Within the first two calendar years following the date of
notification by M.I.T. [**], COMPANY shall expend, or shall cause its
AFFILIATES or SUBLICENSEES to expend, an average of at least ten
thousand dollars ($10,000) per month for the commercial development of
LICENSED PRODUCTS.

          (e)   Beginning on the second anniversary of the date of
notification by M.I.T. [**], COMPANY shall expend, or shall cause its
AFFILIATES or SUBLICENSEES to expend, at least two hundred thousand dollars
($200,000), per each year for the commercial development of LICENSED
PRODUCTS, until a first commercial sale of a LICENSED PRODUCT.

          (f)   COMPANY shall develop or, shall cause its AFFILIATES or
SUBLICENSEES to develop, a working model of a LICENSED PRODUCT on or before the
third anniversary of the date of notification by M.I.T. [**].

          (g)   COMPANY shall make, or shall cause its AFFILIATES or
SUBLICENSEES to make, a first commercial sale of a LICENSED PRODUCT on or before
the fourth anniversary of the date of notification by M.I.T. [**].

          (h)   COMPANY shall sell, or shall cause its AFFILIATES or
SUBLICENSEES to sell, the following numbers of LICENSED PRODUCTS according to
the following schedule:

<Table>
          <S>                                                   <C>
          Calendar Year 1 after the first commercial sale         10 units
          Calendar Year 2 after the first commercial sale         25 units
          Calendar Year 3 after the first commercial sale,
          and each year thereafter                                50 units
</Table>

     3.3. In the event that M.I.T. determines that COMPANY has failed to fulfill
any of its obligations under Section 3.2 above, then M.I.T. may treat such
failure as a material breach in accordance with Section 12.3(b).

                                        9
<Page>

                         4. ROYALTIES AND PAYMENT TERMS.

     4.1 CONSIDERATION FOR GRANT OF RIGHTS.

          (a)   LICENSE ISSUE FEE AND PATENT COST REIMBURSEMENT. COMPANY shall
pay to M.I.T. on the EFFECTIVE DATE a license issue fee of [**] dollars ($[**]).
This payment is nonrefundable.

          (b)   LICENSE MAINTENANCE FEES. COMPANY shall pay to M.I.T. the
following license maintenance fees on the dates set forth below:

<Table>
                <S>                                           <C>
                [**] and each [**]
                        every year through [**]               $ [**]
                [**]                                          $ [**]
                [**]                                          $ [**]
                and each [**]
                   every year thereafter                      $ [**]
</Table>

                This annual license maintenance fee is nonrefundable; however,
the license maintenance fee may be credited to running royalties subsequently
due on NET SALES earned during the same calendar year, if any. License
maintenance fees paid in excess of running royalties due in such calendar year
shall not be creditable to amounts due for future years.

          (c)   RUNNING ROYALTIES. COMPANY shall pay M.I.T. a running royalty of
[**] percent ([**]%) of all NET SALES by COMPANY, AFFILIATES and SUBLICENSEES.
Running royalties shall be payable for each REPORTING PERIOD and shall be due to
M.I.T. within sixty (60) days of the end of each REPORTING PERIOD.

          (d)   SHARING OF SUBLICENSE INCOME. COMPANY shall pay M.I.T. a total
of [**] percent ([**]%) of all SUBLICENSE INCOME received by COMPANY or
AFFILIATES. Such amount shall be payable for each REPORTING PERIOD and shall be
due to M.I.T. within sixty (60) days of the end of each REPORTING PERIOD.

          (e)   NO MULTIPLE ROYALTIES. If the manufacture, use, lease, or sale
of any LICENSED PRODUCT is covered by more than one of the PATENT RIGHTS,
multiple royalties shall NOT be due.

                                       10
<Page>

     4.2 PAYMENTS.

          (a)   METHOD OF PAYMENT. All payments under this Agreement should be
made payable to "Massachusetts Institute of Technology" and sent to the address
identified in Section 14.1. Each payment should reference this Agreement and
identify the obligation under this Agreement that the payment satisfies.

          (b)   PAYMENTS IN U.S. DOLLARS. All payments due under this Agreement
shall be drawn on a United States bank and shall be payable in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the
conversion rate existing in the United States (as reported in the WALL STREET
JOURNAL) on the last working day of the calendar quarter of the applicable
REPORTING PERIOD. Such payments shall be without deduction of exchange,
collection, or other charges, and, specifically, without deduction of
withholding or similar taxes or other government imposed fees or taxes, except
as permitted in the definition of NET SALES.

          (c)   LATE PAYMENTS. Any payments by COMPANY that are not paid on or
before the date such payments are due under this Agreement shall bear interest,
to the extent permitted by law, at two percentage points above the Prime Rate of
interest as reported in the WALL STREET JOURNAL on the date payment is due.

                             5. REPORTS AND RECORDS.

     5.1 FREQUENCY OF REPORTS.

          (a)   BEFORE FIRST COMMERCIAL SALE. Prior to the first commercial sale
of any LICENSED PRODUCT, COMPANY shall deliver reports to M.I.T. annually,
within sixty (60) days of the end of each calendar year, containing information
concerning the immediately preceding calendar year, as further described in
Section 5.2.

          (b)   UPON FIRST COMMERCIAL SALE OF A LICENSED PRODUCT. COMPANY shall
report to M.I.T. the date of first commercial sale of a LICENSED PRODUCT within
sixty (60) days of occurrence in each country.

          (c)   AFTER FIRST COMMERCIAL SALE. After the first commercial sale of
a LICENSED PRODUCT, COMPANY shall deliver reports to M.I.T. within sixty (60)
days of the end of each REPORTING PERIOD, containing information concerning the
immediately preceding REPORTING PERIOD, as further described in Section 5.2.

                                       11
<Page>

     5.2 CONTENT OF REPORTS AND PAYMENTS. Each report delivered by COMPANY to
M.I.T. shall contain at least the following information for the immediately
preceding REPORTING PERIOD:

          (i) the number of LICENSED PRODUCTS sold, leased or distributed by
COMPANY, its AFFILIATES and SUBLICENSEES to INDEPENDENT THIRD PARTIES in each
country, and, if applicable, the number of LICENSED PRODUCTS used by COMPANY,
its AFFILIATES and SUBLICENSEES in the provision of services in each country;

          (ii) the gross price charged by COMPANY, its AFFILIATES and
SUBLICENSEES for each LICENSED PRODUCT in each country;

          (iii) calculation of NET SALES for the applicable REPORTING PERIOD in
each country, including a listing of applicable deductions;

          (iv) total royalty payable on NET SALES in U.S. dollars, together with
the exchange rates used for conversion;

          (v) the amount of SUBLICENSE INCOME received by COMPANY from each
SUBLICENSEE and the amount due to M.I.T. from such SUBLICENSE INCOME, including
an itemized breakdown of the sources of income comprising the SUBLICENSE INCOME;
and

          (vii) the number of sublicenses entered into for the PATENT RIGHTS
and/or LICENSED PRODUCTS.

     If no amounts are due to M.I.T. for any REPORTING PERIOD, the report shall
so state.

     5.3 FINANCIAL STATEMENTS. On or before the ninetieth (90th) day following
the close of COMPANY's fiscal year, COMPANY shall provide M.I.T. with COMPANY's
financial statements for the preceding fiscal year including, at a minimum, a
balance sheet and an income statement, certified by COMPANY's treasurer or chief
financial officer or by an independent auditor.

     5.4 RECORDS. COMPANY shall maintain, and shall cause its AFFILIATES and
SUBLICENSEES to maintain, complete and accurate records relating to the rights
and obligations under this Agreement and any amounts payable to M.I.T. in
relation to this

                                       12
<Page>

Agreement, which records shall contain sufficient information to permit M.I.T.
to confirm the accuracy of any reports delivered to M.I.T. and compliance in
other respects with this Agreement. The relevant party shall retain such records
for at least five (5) years following the end of the calendar year to which they
pertain, during which time M.I.T., or M.I.T.'s appointed agents, shall have the
right, at M.I.T.'s expense, to inspect such records during normal business hours
to verify any reports and payments made or compliance in other respects under
this Agreement. In the event that any audit performed under this Section reveals
an underpayment in excess of five percent (5%), COMPANY shall bear the full cost
of such audit and shall remit any amounts due to M.I.T. within thirty (30) days
of receiving notice thereof from M.I.T.

     5.5 CONFIDENTIAL INFORMATION. The information in the reports and records
provided by COMPANY to M.I.T. pursuant to Sections 5.1 through 5.4 of this
Agreement and in the sublicense agreements provided to M.I.T. under Section 2.3
shall be considered "Confidential Information", provided that such information
is specifically designated in writing as confidential. M.I.T. shall maintain the
Confidential Information in strict confidence, unless, the information (i) was
in the public domain prior to the time of its disclosure under this Agreement;
(ii) entered the public domain after the time of its disclosure under this
Agreement through means other than an unauthorized disclosure resulting from an
act or omission by M.I.T; (iii) was independently developed or discovered by
M.I.T. without use of the Confidential Information; (iv) is or was disclosed to
M.I.T. at any time, whether prior to or after the time of its disclosure under
this Agreement, by a third party having no fiduciary relationship with COMPANY
and having no obligation of confidentiality with respect to such Confidential
Information; or (v) is required to be disclosed to comply with applicable laws
or regulations, or with a court or administrative order.

                             6. PATENT PROSECUTION.

     6.1 RESPONSIBILITY FOR PATENT RIGHTS. M.I.T. shall prepare, file,
prosecute, and maintain all of the PATENT RIGHTS. COMPANY shall have reasonable
opportunities to advise M.I.T. and shall cooperate with M.I.T. in such filing,
prosecution and maintenance. M.I.T. will instruct its patent attorney to copy
COMPANY on all patent prosecution documents relating to PATENT RIGHTS during the
TERM.

     6.2 INTERNATIONAL (NON-UNITED STATES) FILINGS. APPENDIX D is a list of
countries in which patent applications corresponding to the United States patent
applications listed in APPENDIX A, B, AND C shall be filed, prosecuted, and
maintained. APPENDIX D may be amended by mutual agreement of COMPANY and M.I.T.

                                       13
<Page>

     6.3 PAYMENT OF EXPENSES. Should the Amended and Restated Exclusive Patent
License Agreement between M.I.T. and COMPANY, dated November 1, 2002 (the "First
Agreement") be terminated for any reason, payment of all fees and costs,
including attorneys' fees, relating to the filing, prosecution and maintenance
of the PATENT RIGHTS SEQUENCING shall be the responsibility of COMPANY, whether
such amounts were incurred before or after the EFFECTIVE DATE. COMPANY shall
reimburse all amounts due pursuant to this Section within thirty (30) days of
invoicing; late payments shall accrue interest pursuant to Section 4.2(c). In
all instances, M.I.T. shall pay the fees prescribed for large entities to the
United States Patent and Trademark Office. Notwithstanding the first sentence of
this Section, if, after the termination of the First Agreement, M.I.T. licenses
the PATENT RIGHTS SEQUENCING to one or more third parties in a field other than
FIELD SEQUENCING MACHINES, M.I.T. shall promptly notify COMPANY in writing, and
any fees and costs associated with the PATENT RIGHTS SEQUENCING shall be
allocated in a fair and equitable manner between COMPANY and any subsequent
licensees of the PATENT RIGHTS SEQUENCING on a go-forward basis.

                                7. INFRINGEMENT.

     7.1 NOTIFICATION OF INFRINGEMENT. Each party agrees to provide written
notice to the other party promptly after becoming aware of any infringement of
the PATENT RIGHTS.

     7.2 RIGHT TO PROSECUTE INFRINGEMENTS.

          (a)   COMPANY RIGHT TO PROSECUTE PATENT RIGHTS IN EXCLUSIVE FIELDS. So
long as COMPANY remains the exclusive licensee of the PATENT RIGHTS SEQUENCING
and the PATENT RIGHTS HEPARINSE in the FIELD SEQUENCING MACHINES in the
TERRITORY, COMPANY, to the extent permitted by law, shall have the right, under
its own control and at its own expense, to prosecute any third party
infringement of the PATENT RIGHTS SEQUENCING and PATENT RIGHTS HEPARINASE in the
FIELD SEQUENCING MACHINES in the TERRITORY, subject to Sections 7.4 and 7.5. If
required by law, M.I.T. shall permit any action under this Section to be brought
in its name, including being joined as a party-plaintiff, provided that COMPANY
shall hold M.I.T. harmless from, and indemnify M.I.T. against, any costs,
expenses, or liability that M.I.T. incurs in connection with such action. Prior
to commencing any such action, COMPANY shall consult with M.I.T. and shall
consider the views of M.I.T. regarding the advisability of the proposed action
and its effect on the public interest. COMPANY shall not enter into any
settlement, consent judgment, or other voluntary

                                       14
<Page>

final disposition of any infringement action under this Section without the
prior written consent of M.I.T.

          (b)   M.I.T. RIGHT TO PROSECUTE PATENT RIGHTS IN EXCLUSIVE FIELDS. In
the event that COMPANY is unsuccessful in persuading the alleged infringer to
desist or fails to have initiated an infringement action within a reasonable
time after COMPANY first becomes aware of the basis for such action, M.I.T.
shall have the right, at its sole discretion, to prosecute such infringement
under its sole control and at its sole expense, and any recovery obtained shall
belong to M.I.T. If required by law, COMPANY hereby agrees that M.I.T. may
include COMPANY as a party-plaintiff in any such suit, without expense to
COMPANY. Prior to commencing any such action, M.I.T. shall consult with COMPANY
and shall consider the views of COMPANY regarding the advisability of the
proposed action. Further, M.I.T. shall not enter into any settlement, consent
judgment, or other voluntary final disposition of any infringement action under
this Section without first consulting with and considering the views of COMPANY.
Notwithstanding the forgoing, any action taken under this Section shall be at
the sole discretion of M.I.T.

          (c)   M.I.T. RIGHT TO PROSECUTE PATENT RIGHTS IN NON-EXCLUSIVE FIELDS.
M.I.T. shall have the right, but shall not be obligated, to prosecute at its
sole control and sole expense all infringements of PATENT RIGHTS MASS SPEC and
M.I.T. shall keep any recovery or damages derived therefrom, whether
compensatory for past infringement or punitive. If required by law, COMPANY
hereby agrees that M.I.T. may include COMPANY as a party plaintiff in any such
suit, without expense to COMPANY. Prior to commencing any such action, M.I.T.
shall consult with COMPANY and shall consider the views of COMPANY regarding the
advisability of the proposed action. Further, M.I.T. shall not enter into any
settlement, consent judgment, or other voluntary final disposition of any
infringement action under this Section without first consulting with and
considering the views of COMPANY. Lastly, in the event that COMPANY approaches
M.I.T. and requests that M.I.T. commence the prosecution of an infringement of
any of the PATENT RIGHTS MASS SPEC, M.I.T. agrees to give due consideration to
the views of the COMPANY. Notwithstanding the forgoing, any action taken under
this Section shall be at the sole discretion of M.I.T.

     7.3 DECLARATORY JUDGMENT ACTIONS. In the event that a declaratory judgment
action is brought against M.I.T. or COMPANY by a third party alleging
invalidity, unenforceability, or non-infringement of the PATENT RIGHTS, M.I.T.,
at its option, shall have the right within twenty (20) days after commencement
of such action to take over the sole defense of the action at

                                       15
<Page>

its own expense. If M.I.T. does not exercise this right, COMPANY may take over
the sole defense of the action at COMPANY's sole expense, subject to Sections
7.4 and 7.5.

     7.4 OFFSETS. COMPANY may offset a total of [**] percent ([**]%) of any
expenses incurred under Sections 7.2 and 7.3 against any payments due to M.I.T.
under Article 4, provided that in no event shall such payments under Article 4,
when aggregated with any other offsets and credits allowed under this Agreement,
be reduced by more than [**] percent ([**]%) in any REPORTING PERIOD.

     7.5 RECOVERY. Any recovery obtained in an action brought by COMPANY under
Sections 7.2 or 7.3 shall be distributed as follows: (i) each party shall be
reimbursed for any expenses incurred in the action (including the amount of any
royalty or other payments withheld from M.I.T. as described in Section 7.4),
(ii) as to ordinary damages, COMPANY shall receive an amount equal to its lost
profits or a reasonable royalty on the infringing sales, or whichever measure of
damages the court shall have applied, and COMPANY shall pay to M.I.T. based upon
such amount a reasonable approximation of the royalties and other amounts that
COMPANY would have paid to M.I.T. if COMPANY had sold the infringing products,
processes and services rather than the infringer, and (iii) as to special or
punitive damages, [**].

     7.6 COOPERATION. Each party agrees to cooperate in any action under this
Article, which is controlled by the other party, provided that the controlling
party reimburses the cooperating party promptly for any costs and expenses
incurred by the cooperating party in connection with providing such assistance.

     7.7 RIGHT TO SUBLICENSE. So long as COMPANY remains the exclusive licensee
of the PATENT RIGHTS SEQUENCING and the PATENT RIGHTS HEPARINASE in the FIELD
SEQUENCING MACHINES in the TERRITORY, COMPANY shall have the sole right to
sublicense any alleged infringer in the FIELD SEQUENCING MACHINES in the
TERRITORY for future use of the PATENT RIGHTS SEQUENCING and PATENT RIGHTS
HEPARINASE in accordance with the terms and conditions of this Agreement
relating to sublicenses. Any upfront fees as part of such sublicense shall [**];
other revenues to COMPANY pursuant to such sublicense shall be treated as set
forth in Article 4.

                                       16
<Page>

                        8. INDEMNIFICATION AND INSURANCE.

     8.1 INDEMNIFICATION.

          (a)   INDEMNITY. COMPANY shall indemnify, defend, and hold harmless
M.I.T. and its trustees, officers, faculty, students, employees, and agents and
their respective successors, heirs and assigns (the "Indemnitees"), against any
liability, damage, loss, or expense (including reasonable attorneys fees and
expenses) incurred by or imposed upon any of the Indemnitees in connection with
any claims, suits, actions, demands or judgments arising out of any theory of
liability (including without limitation actions in the form of tort, warranty,
or strict liability and regardless of whether such action has any factual basis)
concerning any product, process, or service that is made, used, sold, imported,
or performed pursuant to any right or license granted under this Agreement.

          (b)   PROCEDURES. The Indemnitees agree to provide COMPANY with prompt
written notice of any claim, suit, action, demand, or judgment for which
indemnification is sought under this Agreement. COMPANY agrees, at its own
expense, to provide attorneys reasonably acceptable to M.I.T. to defend against
any such claim. The Indemnitees shall cooperate fully with COMPANY in such
defense and will permit COMPANY to conduct and control such defense and the
disposition of such claim, suit, or action (including all decisions relative to
litigation, appeal, and settlement); provided, however, that any Indemnitee
shall have the right to retain its own counsel, at the expense of COMPANY, if
representation of such Indemnitee by the counsel retained by COMPANY would be
inappropriate because of actual or potential differences in the interests of
such Indemnitee and any other party represented by such counsel. COMPANY agrees
to keep M.I.T. informed of the progress in the defense and disposition of such
claim and to consult with M.I.T. with regard to any proposed settlement.

          8.2   INSURANCE. COMPANY shall obtain and carry in full force and
effect commercial general liability insurance, including product liability and
errors and omissions insurance which shall protect COMPANY and Indemnitees with
respect to events covered by Section 8.1(a) above. Such insurance (i) shall be
issued by an insurer licensed to practice in the Commonwealth of Massachusetts
or an insurer pre-approved by M.I.T., such approval not to be unreasonably
withheld, (ii) shall list M.I.T. as an additional insured thereunder, (iii)
shall be endorsed to include product liability coverage, and (iv) shall require
thirty (30) days written notice to be given to M.I.T. prior to any cancellation
or material change thereof. The limits of such insurance shall not be less than
One Million Dollars ($1,000,000) per occurrence with an aggregate of Three
Million Dollars ($3,000,000) for bodily injury including death; One Million

                                       17
<Page>

Dollars ($1,000,000) per occurrence with an aggregate of Three Million Dollars
($3,000,000) for property damage; and One Million Dollars ($1,000,000) per
occurrence with an aggregate of Three Million Dollars ($3,000,000) for errors
and omissions. In the alternative, COMPANY may self-insure subject to prior
approval of M.I.T. COMPANY shall provide M.I.T. with Certificates of Insurance
evidencing compliance with this Section. COMPANY shall continue to maintain such
insurance or self-insurance after the expiration or termination of this
Agreement during any period in which COMPANY or any AFFILIATE or SUBLICENSEE
continues to make, use, or sell a product that was a LICENSED PRODUCT under this
Agreement and thereafter for a period of five (5) years.

                      9. NO REPRESENTATIONS OR WARRANTIES.

     M.I.T. hereby represents and warrants that, to the best of its knowledge on
the EFFECTIVE DATE: (i) it is the sole owner of all PATENT RIGHTS other than the
PATENT RIGHTS for M.I.T. Case [**], which are jointly owned by M.I.T. and the
[**], and the PATENT RIGHTS for M.I.T. Case [**], which are owned jointly by
M.I.T. and [**], and (ii) has the right to grant the licenses granted herein.
M.I.T.'s total liability under the representations and warranties of this
Agreement shall be limited to an amount equal to the total sum that has been
paid by COMPANY to M.I.T. under the provisions of Article 4 of this Agreement
and any payments that have been made by COMPANY to M.I.T. under Section 6.3

     EXCEPT AS MAY OTHERWISE BE EXPRESSLY SET FORTH IN THIS AGREEMENT, M.I.T.
MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS
CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS,
WHETHER OR NOT DISCOVERABLE. Specifically, and not to limit the foregoing,
M.I.T. makes no warranty or representation (i) regarding the validity or scope
of the PATENT RIGHTS, and (ii) that the exploitation of the PATENT RIGHTS or any
LICENSED PRODUCT will not infringe any patents or other intellectual property
rights of M.I.T. or of a third party.

     IN NO EVENT SHALL M.I.T., ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND
AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND,
INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF
WHETHER M.I.T. SHALL BE

                                       18
<Page>

ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY OF THE FOREGOING.

                                 10. ASSIGNMENT.

     This Agreement is personal to COMPANY and no rights or obligations may be
assigned by COMPANY, except that COMPANY may assign this Agreement, upon written
notice to M.I.T. and without M.I.T.'s consent, in conjunction with the sale or
transfer of all or substantially all of its assets related to the
commercialization of the PATENT RIGHTS, or pursuant to a merger or
consolidation, to or into an entity which has agreed in writing to be bound by
all the terms and conditions of this Agreement. Failure of the assignee to so
agree shall be grounds for termination by M.I.T.

                        11. GENERAL COMPLIANCE WITH LAWS.

     11.1 COMPLIANCE WITH LAWS. COMPANY shall use reasonable commercial efforts
to comply with all commercially material local, state, federal, and
international laws and regulations relating to the development, manufacture,
use, and sale of LICENSED PRODUCTS.

     11.2 EXPORT CONTROL. COMPANY and its AFFILIATES and SUBLICENSEES shall
comply with all United States laws and regulations controlling the export of
certain commodities and technical data, including without limitation all Export
Administration Regulations of the United States Department of Commerce. Among
other things, these laws and regulations prohibit or require a license for the
export of certain types of commodities and technical data to specified
countries. COMPANY hereby gives written assurance that it will comply with, and
will cause its AFFILIATES and SUBLICENSEES to comply with, all United States
export control laws and regulations, that it bears sole responsibility for any
violation of such laws and regulations by itself or its AFFILIATES or
SUBLICENSEES, and that it will indemnify, defend, and hold M.I.T. harmless (in
accordance with Section 8.1) for the consequences of any such violation.

     11.3 NON-USE OF M.I.T. NAME. COMPANY and its AFFILIATES and SUBLICENSEES
shall not use the name of "Massachusetts Institute of Technology," "Lincoln
Laboratory" or any variation, adaptation, or abbreviation thereof, or of any of
its trustees, officers, faculty, students, employees, or agents, or any
trademark owned by M.I.T., or any terms of this Agreement in any promotional
material or other public announcement or disclosure without the prior written
consent of M.I.T. The foregoing notwithstanding, without the consent of M.I.T.,
COMPANY

                                       19
<Page>

may state that it is licensed by M.I.T. under one or more of the patents and/or
patent applications comprising the PATENT RIGHTS.

     11.4 MARKING OF LICENSED PRODUCTS. To the extent commercially feasible and
consistent with prevailing business practices, COMPANY shall mark, and shall
cause its AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS that are
manufactured or sold under this Agreement with the number of each issued patent
under the PATENT RIGHTS that applies to such LICENSED PRODUCT.

                                12. TERMINATION.

     12.1 VOLUNTARY TERMINATION BY COMPANY. COMPANY shall have the right to
terminate this Agreement, for any reason, (i) upon at least six (6) months prior
written notice to M.I.T., such notice to state the date at least six (6) months
in the future upon which termination is to be effective, and (ii) upon payment
of all amounts due to M.I.T. through such termination effective date.

     12.2 CESSATION OF BUSINESS. If COMPANY ceases to carry on its business
related to this Agreement, M.I.T. shall have the right to terminate this
Agreement immediately upon written notice to COMPANY.

     12.3 TERMINATION FOR DEFAULT.

          (a)   NONPAYMENT. In the event COMPANY fails to pay any amounts due
and payable to M.I.T. hereunder, and fails to make such payments within sixty
(60) days after receiving written notice of such failure, M.I.T. may terminate
this Agreement immediately upon written notice to COMPANY.

          (b)   MATERIAL BREACH. In the event COMPANY commits a material breach
of its obligations under this Agreement, except for breach as described in
Section 12.3(a), and fails to cure that breach within ninety (90) days after
receiving written notice thereof, M.I.T. may terminate this Agreement
immediately upon written notice to COMPANY.

                                       20
<Page>

     12.4 EFFECT OF TERMINATION.

          (a)   SURVIVAL. The following provisions shall survive the expiration
or termination of this Agreement: Articles 1, 8, 9, 13 and 14, and Sections 5.2
(obligation to provide final report and payment), 5.4, 5.5, 11.1, 11.2 and 12.4.

          (b)   INVENTORY. Upon the early termination of this Agreement, COMPANY
and its AFFILIATES and SUBLICENSEES may complete and sell any work-in-progress
and inventory of LICENSED PRODUCTS that exist as of the effective date of
termination, provided that (i) COMPANY pays M.I.T. the applicable running
royalty or other amounts due on such sales of LICENSED PRODUCTS in accordance
with the terms and conditions of this Agreement, and (ii) COMPANY and its
AFFILIATES and SUBLICENSEES shall complete and sell all work-in-progress and
inventory of LICENSED PRODUCTS within six (6) months after the effective date of
termination.

          (c)   PRE-TERMINATION OBLIGATIONS. In no event shall termination of
this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the obligation
to pay any amounts that became due on or before the effective date of
termination.

                             13. DISPUTE RESOLUTION.

     13.1 MANDATORY PROCEDURES. The parties agree that any dispute arising out
of or relating to this Agreement shall be resolved solely by means of the
procedures set forth in this Article, and that such procedures constitute
legally binding obligations that are an essential provision of this Agreement.
If either party fails to observe the procedures of this Article, as may be
modified by their written agreement, the other party may bring an action for
specific performance of these procedures in any court of competent jurisdiction.

     13.2 EQUITABLE REMEDIES. Although the procedures specified in this Article
are the sole and exclusive procedures for the resolution of disputes arising out
of or relating to this Agreement, either party may seek a preliminary injunction
or other provisional equitable relief if, in its reasonable judgment, such
action is necessary to avoid irreparable harm to itself or to preserve its
rights under this Agreement.

                                       21
<Page>

     13.3 DISPUTE RESOLUTION PROCEDURES.

          (a)   MEDIATION. In the event any dispute arising out of or relating
to this Agreement remains unresolved within sixty (60) days from the date the
affected party informed the other party of such dispute, either party may
initiate mediation upon written notice to the other party ("Notice Date"),
whereupon both parties shall be obligated to engage in a mediation proceeding
under the then current Center for Public Resources ("CPR") Model Procedure for
Mediation of Business Disputes (http://www.cpradr.org), except that specific
provisions of this Article shall override inconsistent provisions of the CPR
Model Procedure. The mediator will be selected from the CPR Panels of Neutrals.
If the parties cannot agree upon the selection of a mediator within fifteen (15)
business days after the Notice Date, then upon the request of either party, the
CPR shall appoint the mediator. The parties shall attempt to resolve the dispute
through mediation until the first of the following occurs: (i) the parties reach
a written settlement; (ii) the mediator notifies the parties in writing that
they have reached an impasse; (iii) the parties agree in writing that they have
reached an impasse; or (iv) the parties have not reached a settlement within
sixty (60) days after the Notice Date.

          (b)   TRIAL WITHOUT JURY. If the parties fail to resolve the dispute
through mediation, or if neither party elects to initiate mediation, each party
shall have the right to pursue any other remedies legally available to resolve
the dispute, provided, however, that the parties expressly waive any right to a
jury trial in any legal proceeding under this Article.

     13.4 PERFORMANCE TO CONTINUE. Each party shall continue to perform its
undisputed obligations under this Agreement pending final resolution of any
dispute arising out of or relating to this Agreement; provided, however, that a
party may suspend performance of its undisputed obligations during any period in
which the other party fails or refuses to perform its undisputed obligations.
Nothing in this Article is intended to relieve COMPANY from its obligation to
make undisputed payments pursuant to Articles 4 and 6 of this Agreement.

     13.5 STATUTE OF LIMITATIONS. The parties agree that all applicable statutes
of limitation and time-based defenses (such as estoppel and laches) shall be
tolled while the procedures set forth in Sections 13.3(a) are pending. The
parties shall cooperate in taking any actions necessary to achieve this result.

                                       22
<Page>

                               14. MISCELLANEOUS.

     14.1 NOTICE. Any notices required or permitted under this Agreement shall
be in writing, shall specifically refer to this Agreement, and shall be sent by
hand, recognized national overnight courier, confirmed facsimile transmission,
confirmed electronic mail, or registered or certified mail, postage prepaid,
return receipt requested, to the following addresses or facsimile numbers of the
parties:

     If to M.I.T.:

                     Technology Licensing Office, Room NE25-230
                     Massachusetts Institute of Technology
                     77 Massachusetts Avenue
                     Cambridge, MA 02139-4307
                     Attention:  Director
                     Tel:  617-253-6966
                     Fax:  617-258-6790

     If to COMPANY:

                     43 Moulton Street
                     Cambridge, MA 02138
                     Attention:  Chief Executive Officer
                     Tel: 617-491-9700
                     Fax: 617-491-9701

          All notices under this Agreement shall be deemed effective upon
receipt. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section.

     14.2 GOVERNING LAW. This Agreement and all disputes arising out of or
related to this Agreement, or the performance, enforcement, breach or
termination hereof, and any remedies relating thereto, shall be construed,
governed, interpreted and applied in accordance with the laws of the
Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws
principles, except that questions affecting the construction and effect of any
patent shall be determined by the law of the country in which the patent shall
have been granted.

     14.3 FORCE MAJEURE. Neither party will be responsible for delays resulting
from causes beyond the reasonable control of such party, including without
limitation fire, explosion, flood, war, strike, or riot, provided that the
nonperforming party uses commercially reasonable efforts

                                       23
<Page>

to avoid or remove such causes of nonperformance and continues performance under
this Agreement with reasonable dispatch whenever such causes are removed.

     14.4 AMENDMENT AND WAIVER. This Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both parties.
Any waiver of any rights or failure to act in a specific instance shall relate
only to such instance and shall not be construed as an agreement to waive any
rights or fail to act in any other instance, whether or not similar.

     14.5 SEVERABILITY. In the event that any provision of this Agreement shall
be held invalid or unenforceable for any reason, such invalidity or
unenforceability shall not affect any other provision of this Agreement, and the
parties shall negotiate in good faith to modify the Agreement to preserve (to
the extent possible) their original intent. If the parties fail to reach a
modified agreement within thirty (30) days after the relevant provision is held
invalid or unenforceable, then the dispute shall be resolved in accordance with
the procedures set forth in Article 13. While the dispute is pending resolution,
this Agreement shall be construed as if such provision were deleted by agreement
of the parties.

     14.6 BINDING EFFECT. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective permitted successors and assigns.

     14.7 HEADINGS. All headings are for convenience only and shall not affect
the meaning of any provision of this Agreement.

     14.8 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties with respect to its subject matter and supersedes all prior
agreements or understandings between the parties relating to its subject matter.

                                       24
<Page>

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives.

THE EFFECTIVE DATE OF THIS AGREEMENT IS OCTOBER 31, 2002.

MASSACHUSETTS INSTITUTE OF                 MOMENTA PHARMACEUTICALS, INC.
TECHNOLOGY

By  /s/ LITA NELSEN                        By  /s/ S.K. WHORISKEY, PH.D.
   ------------------------------------       ----------------------------------
Name  Lita L. Nelsen                       Name  Susan K Whoriskey
     ----------------------------------         --------------------------------
Title  Director, Technology Licensing      Title  Vice President, Licensing and
       Office                                     Business Development
      ---------------------------------          -------------------------------

                                       25
<Page>

                                   APPENDIX A

                   LIST OF PATENT APPLICATIONS AND PATENTS FOR
                            PATENT RIGHTS HEPARINASE

I.   UNITED STATES PATENTS AND APPLICATIONS

     M.I.T. CASE NO. 5546
     Entitled M.I.T. Case No. 5546, "The Heparinase Gene from Flavobacterium
     Heparinum",
     By Charles L. Cooney, Robert S. Langer, Jr., Kelley W. Moreman, And Ram
     Sasisekharan

         USA Patent No. 5714376, Issued February 3, 1998
         Entitled "The Heparinase Gene from Flavobacterium Heparinum"

         USA Patent No. 5830726, Issued November 3, 1998
         Entitled "Method for Obtaining a Modified Heparinase Gene"

     M.I.T. CASE NO. 5981
     Entitled "Purification, Composition And Characterization Of Heparinase II
     From Flavobacterium Heparinum"
     By Charles L. Cooney, Robert S. Langer, Jr., Robert Lindhardt, Daniel
     Lohse, And Ram Sasisekharan

         USA Patent No. 5389539, Issued February 14, 1995
         Entitled "Purification, Composition and Specificity of Heparinase I,
         II, and III from Flavobacterium Heparinum"

         USA Patent No. 5569600, Issued October 29, 1996
         Entitled "Purification, Composition and Specificity of Heparinase I, II
         & III from Flavobacterium Heparinum"

II.  INTERNATIONAL (NON-U.S.) PATENTS AND APPLICATIONS

     M.I.T. CASE NO. [**]

     Entitled [**]

          AT Patent No. [**].
          BE Patent No. [**].
          CH Patent No. [**].
          DE Patent No. [**].
          DK Patent No. [**].
          ES Patent No. [**].
          FR Patent No. [**].
          GB Patent No. [**]
          GR Patent No. [**]
          IE Patent No. [**]
          IT Patent No. [**].
          LI Patent No. [**].
          LU Patent No. [**].
          MC Patent No. [**].
          NL Patent No. [**]
          SE Patent No. [**]
          All Entitled: [**]

                                       26
<Page>

          CA Patent Application Serial No. [**]
          Entitled: [**]

          JP Patent Application Serial No. [**]
          Entitled: [**]

     M.I.T. CASE NO. [**]
     Entitled [**]

          EP Patent No. [**]
          Entitled: [**]

          CA Patent No. [**]
          Entitled: [**]

          JP Patent Application Serial No. [**]
          Entitled: [**]

                                       27
<Page>

                                   APPENDIX B

                   LIST OF PATENT APPLICATIONS AND PATENTS FOR
                              PATENT RIGHTS MASSPEC

I.   UNITED STATES PATENTS AND APPLICATIONS

     M.I.T. CASE NO. 6582
     Entitled: "A Method for the Mass Spectrometric Determination of the
Molecular Weight of Highly Acidic (and Basic) Organic and Biological
Molecules"
By Klaus Biemann and Peter Juhasz

          USA Patent No. 5,607,859, Issued March 4, 1997
          Entitled: "Methods and Products for Mass Spectrometric Molecular
Weight Determination of Polyionic Analytes Employing Polyionic Reagents"

                                       28
<Page>

     APPENDIX C

                   LIST OF PATENT APPLICATIONS AND PATENTS FOR
                            PATENT RIGHTS SEQUENCING

I.   UNITED STATES PATENTS AND APPLICATIONS

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No. [**]
          Entitled:[**]

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No. [**]
          Entitled: [**]

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No.[**]
          Entitled:[**]

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No. [**]
          Entitled:  [**]

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No.[**]
          Entitled:  [**]

          M.I.T. CASE NO. [**]
          Entitled: [**]

          USA Serial No.[**]
          Entitled:  [**]

          M.I.T. CASE NO. [**]
          Entitled:[**]

          USA Serial No. [**]
          Entitled: [**]

                                       29
<Page>

II.  INTERNATIONAL (NON-U.S.) PATENTS AND APPLICATIONS

     M.I.T. CASE NO. [**]
     Entitled: [**]

          EPC Application No. [**]
          Entitled:  [**]

          Canada Application No.  [**]
          Entitled:  [**]

          Japanese Application No. [**]
          Entitled: [**]

     M.I.T. CASE NO. [**]
     Entitled: [**]

          EPC Application No. [**]
          Entitled: [**]

          Canada Application No. [**]
          Entitled: [**]

          Japanese Application No. [**]
          Entitled: [**]

     M.I.T. CASE NO. [**]
     Entitled: [**]

          WO Application Serial No[**]
          Entitled [**]

     M.I.T. CASE NO. [**]
     Entitled: [**]

          WO Application Serial No. [**]
          Entitled: [**]

     M.I.T. CASE NO. [**]
     Entitled: [**]

          WO Application Serial No. [**]
                                         Entitled: [**]

                                       30
<Page>

                                   APPENDIX D

              LIST OF COUNTRIES (EXCLUDING UNITED STATES) FOR WHICH
       PATENT RIGHTS APPLICATIONS WILL BE FILED, PROSECUTED AND MAINTAINED

                              PCT Designating: [**]

                                       31
<Page>

                 FIRST AMENDMENT TO THE OCTOBER 31, 2002 LICENSE

     This First Amendment, effective as of the date set forth above the
signatures of the parties below, pertains to the Exclusive Patent License
Agreement, effective on October 31, 2002, by and between the Massachusetts
Institute of Technology ("M.I.T.") and Momenta Pharmaceuticals, Inc.
("COMPANY").

     WHEREAS, M.I.T. is the owner of certain new intellectual property closely
related to the PATENT RIGHTS of the Exclusive Patent License Agreement and
desires to have this technology developed and commercialized to benefit the
public; and

     WHEREAS, COMPANY desires to add this new technology to the PATENT RIGHTS
and M.I.T. is willing to grant a license thereunder.

     NOW, THEREFORE, M.I.T. and COMPANY hereby agree to modify the Exclusive
Patent License Agreement as follows:

     1.   The following definition shall be added to Section 1:

               "PATENT RIGHTS ENZYMES" shall mean the PATENT RIGHTS listed in
               APPENDIX E.

     2.   The definition of PATENT RIGHTS under Section 1.20 shall be modified
          to read:

               "PATENT RIGHTS" shall mean:

               (a)   the United States and international patents listed on
               APPENDICES A THROUGH C, AND E;

               (b)   the United States and international patent applications
               and/or provisional applications listed on APPENDICES A THROUGH C,
               AND E; and the resulting patents;

               (c)   any patent applications resulting from the provisional
               applications listed on APPENDICES A THROUGH C, AND E; and any
               divisionals, continuations, continuation-in-part applications,
               and continued prosecution applications (and their relevant
               international equivalents) of the patent applications listed on
               APPENDICES A THROUGH C, AND E; and of such patent applications
               that result from the provisional applications listed on
               APPENDICES A THROUGH C, AND E, to the extent the claims are
               directed to subject matter specifically described in the patent
               applications listed on APPENDICES A THROUGH C, AND E, and the

                                        2
<Page>

               resulting patents;

               (d)   any patents resulting from reissues, reexaminations, or
               extensions (and their relevant international equivalents) of the
               patents described in (a), (b), and (c) above; and

               (e)   international (non-United States) patent applications and
               provisional applications filed after the EFFECTIVE DATE and the
               relevant international equivalents to divisionals, continuations,
               continuation-in-part applications and continued prosecution
               applications of the patent applications to the extent the claims
               are directed to subject matter specifically described in the
               patents or patent applications referred to in (a), (b), (c), and
               (d) above, and the resulting patents.

     3.   Section 2.1 shall be modified to read:

               2.1   LICENSE GRANTS. Subject to the terms of this Agreement,
               M.I.T. hereby grants to COMPANY and its AFFILIATES for the TERM a
               royalty-bearing license under M.I.T.'s rights in the PATENT
               RIGHTS HEPARINASE, the PATENT RIGHTS MASSPEC, the PATENT RIGHTS
               SEQUENCING and the PATENT RIGHTS ENZYMES to develop, make, have
               made, use, sell, offer to sell, lease, and import LICENSED
               PRODUCTS in the FIELD SEQUENCING MACHINES in the TERRITORY.

     4.   The first paragraph of Section 2.2 shall be modified to read:

               2.2   EXCLUSIVITY. In order to establish an exclusive period for
               COMPANY and its AFFILIATES, M.I.T. agrees that it shall not grant
               any other license for PATENTS RIGHTS HEPARINASE, PATENT RIGHTS
               SEQUENCING, and PATENT RIGHTS ENZYMES in FIELD SEQUENCING
               MACHINES to develop, make, have made, use, sell, offer to sell,
               lease and import LICENSED PRODUCTS during the TERM.

     5.   The last sentence of Section 2.2 shall be modified to read:

               Upon COMPANY's exercise of such right, the Appendix of this
               Agreement that describes the PATENT RIGHTS that dominate the
               IMPROVEMENT shall be deemed to have been amended to add the
               invention disclosure (and any related patent applications)
               covering such IMPROVEMENT, and such IMPROVEMENT and any resulting
               patent applications and patents shall thereafter be included in
               PATENT RIGHTS for all purposes of this Agreement, without any
               additional fee, other than the [**] Dollar fee referred to in the
               previous sentence, and M.I.T. shall provide COMPANY with an
               updated APPENDIX A, C, OR E for its records.

                                        3
<Page>

     6.   The patent rights of the following M.I.T. Case Nos. shall be added to
          the PATENT RIGHTS ENZYMES and the PATENT RIGHTS, as defined by its
          inclusion in the attached APPENDIX E:
               M.I.T. CASE NO.[**]
               Entitled: [**]

               M.I.T. Case No. [**]M.I.T. Case No. [**]Entitled: [**]

     7.   In consideration of the addition of the PATENT RIGHTS ENZYMES to the
          PATENT RIGHTS of this Agreement and the license granted in the FIELD
          SEQUENCING MACHINES hereunder:

          a.   COMPANY shall pay M.I.T. a Patent Addition Fee of [**] dollars
               ($[**]) for each M.I.T. Case added for a total of [**] dollars
               ($[**]), which shall be due within thirty (30) days of the
               Effective Date of this First Amendment; and

          b.   Should the First Agreement (as defined under Section 6.3) be
               terminated for any reason, COMPANY shall be responsible for
               payment of all fees and costs relating to the filing, prosecution
               and maintenance of patent rights of M.I.T. Case Nos. [**],
               whether such fees and costs were incurred before or after the
               Effective Date of this First Amendment; provided, however, that
               should M.I.T. license the PATENT RIGHTS ENZYMES to one or more
               third parties in a field other than FIELD SEQUENCING MACHINES,
               M.I.T. shall promptly notify COMPANY in writing and any fees and
               costs associated with PATENT RIGHTS ENZYMES shall be allocated in
               a fair and equitable manner between COMPANY and any subsequent
               licensees of the PATENT RIGHTS ENZYMES on a go-forward basis.

     8.   Section 7.2(a) shall be modified to read:

               COMPANY RIGHT TO PROSECUTE PATENT RIGHTS IN EXCLUSIVE FIELDS. So
               long as COMPANY remains the exclusive licensee of the PATENT
               RIGHTS SEQUENCING, the PATENT RIGHTS HEPARINSE and the PATENT
               RIGHTS ENZYMES in the FIELD SEQUENCING MACHINES in the TERRITORY,
               COMPANY, to the extent permitted by-law, shall have the right,
               under its own control and at its own expense, to prosecute any
               third party infringement of the PATENT RIGHTS SEQUENCING, PATENT
               RIGHTS HEPARINASE and PATENT RIGHTS ENZYMES in the FIELD
               SEQUENCING MACHINES in the TERRITORY, subject to Sections 7.4 and
               7.5. If required by law, M.I.T. shall permit any action under
               this Section to be brought in its name, including being joined as
               a party, plaintiff, provided that COMPANY shall hold M.I.T.
               harmless from, and indemnify M.I.T. against, any costs, expenses,
               or liability that M.I.T. incurs in connection with such action.
               Prior to commencing any such action, COMPANY shall consult with
               M.I.T. and shall consider the views of M.I.T. regarding the
               advisability of the proposed action and its effect on the public
               interest. COMPANY shall

                                        4
<Page>

               not enter into any settlement, consent judgment, or other
               voluntary final disposition of any infringement action under this
               Section without the prior written consent of M.I.T.

     9.   Section 7.7 shall be modified to read:

               RIGHT TO SUBLICENSE. So long as COMPANY remains the exclusive
               licensee of the PATENT RIGHTS SEQUENCING, the PATENT RIGHTS
               HEPARINASE and the PATENT RIGHTS ENZYMES in the FIELD SEQUENCING
               MACHINES in the TERRITORY, COMPANY shall have the sole right to
               sublicense any alleged infringer in the FIELD SEQUENCING MACHINES
               in the TERRITORY for future use of the PATENT RIGHTS SEQUENCING,
               PATENT RIGHTS HEPARINASE and PATENT RIGHTS ENZYMES in accordance
               with the terms and conditions of this Agreement relating to
               sublicenses. Any upfront fees as part of such sublicense shall
               [**]; other revenues to COMPANY pursuant to such sublicense shall
               be treated as set forth in Article 4.

All other terms and conditions of the License Agreement shall remain unchanged.

THE EFFECTIVE DATE OF THIS AMENDMENT IS NOVEMBER 15, 2002.

Agreed to for:

MASSACHUSETTS INSTITUTE OF                  MOMENTA PHARMACEUTICALS, INC.
TECHNOLOGY

By:    /s/ LITA NELSEN                      By:    /s/ SUSAN K. WHORISKEY
   --------------------------------------         ------------------------------
Name:  Lita L. Nelsen                       Name:  Susan K. Whoriskey, Ph.D.
     ------------------------------------         ------------------------------
Title: Director, Technology Licensing       Title: Vice President, Licensing &
       Office                                      Business Development
      -----------------------------------          -----------------------------
Date:   Dec. 20, 2002                       Date:
     ------------------------------------          -----------------------------

                                        5
<Page>

                                   APPENDIX E

                              PATENT RIGHTS ENZYMES

M.I.T. CASE NO. [**]
Entitled: [**]

     United States of America Serial No. [**]
     Entitled: [**]

M.I.T. CASE NO. [**]
Entitled: [**]

        [**].

M.I.T. CASE NO. [**]
Entitled: [**]
[**]

        [**].<Page>

                                                                    Exhibit 10.7

          Confidential Materials omitted and filed separately with the
      Securities and Exchange Commission. Asterisks denote such omissions.

                                LICENSE AGREEMENT

                                       FOR

               INSTALLING NOVEL FUNCTIONAL GROUPS FOR THERAPEUTICS

                                     BETWEEN

                          MOMENTA PHARMACEUTICALS, INC.

                                       AND

                   THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

                                   THROUGH THE

                             ERNEST ORLANDO LAWRENCE
                          BERKELEY NATIONAL LABORATORY

<Page>

                                                                       L-03-1370

                                TABLE OF CONTENTS

<Table>
<S>                                                                          <C>
1.   BACKGROUND                                                               1
2.   DEFINITIONS                                                              1
3.   LICENSE GRAND                                                            3
4.   INFORMATION RIGHTS                                                       4
5.   SUBLICENSING                                                             5
6.   LICENSE ISSUE FEE                                                        5
7.   ROYALTIES AND PAYMENTS                                                   6
8.   PERFORMANCE REQUIREMENTS                                                 8
9.   PROGRESS AND ROYALTY REPORTS                                             8
10.  BOOKS AND RECORDS                                                        9
11.  LIFE OF THE AGREEMENT                                                   10
12.  TERMINATION BY EITHER PARTY                                             11
13.  TERMINATION BY LICENSEE                                                 11
14.  DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION                       11
15.  USE OF NAMES AND NONDISCLOSURE OBLIGATIONS                              11
16.  LIMITED WARRANTY                                                        12
17.  PATENTING AND FOREIGN RIGHTS                                            13
18.  PATENT INFRINGEMENT                                                     14
19.  WAIVER                                                                  15
20.  ASSIGNMENT                                                              16
21.  INDEMNIFICATION                                                         16
22.  LATE PAYMENTS                                                           17
23.  NOTICES                                                                 17
24.  U.S. MANUFACTURE                                                        18
25.  PATENT l1LAREJNNG                                                       18
26.  GOVERNMENT APPROVAL OR REGISTRATION                                     18
27.  EXPORT CONTROL LAWS                                                     18
28.  FORCE MAJEURE                                                           19
29.  MISCELLANEOUS                                                           19

Exhibit A                                                                    19
Exhibit B                                                                    20
Exhibit C                                                                    21
</Table>

<Page>

                                                                       L-03-1370

                              LICENSE AGREEMENT FOR
               INSTALLING NOVEL FUNCTIONAL GROUPS FOR THERAPEUTICS

This license agreement (the "Agreement") is entered into by The Regents of the
University of California, Department of Energy contract-operators of the Ernest
Orlando Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA
94720, ("Berkeley Lab"), and Momenta Pharmaceuticals, Inc. ("Licensee") having
its principal place of business at 43 MoultonStreet, Cambridge, MA 02138.

                                  1. BACKGROUND

1.1.    Certain inventions, generally characterized as Methods For Installing
        Novel Functional Groups On Cells And Cellular Products And Applications
        Thereof, as described in Berkeley Lab case [**], (the "Invention"), were
        made in the course of research at Berkeley Lab under Berkeley Lab's
        contract with the United States Department of Energy ("DOE").

1.2.    As DOE sponsored development of the Invention, this Agreement and the
        resulting license are subject to overriding obligations to the federal
        government pursuant to the provisions of the applicable law or
        regulations.

1.3.    Berkeley Lab wants the Invention developed and used to the fullest
        extent so that the general public enjoys the benefits of the
        government-sponsored research.

1.4.    Licensee wants to obtain certain rights from Berkeley Lab for the
        commercial development, manufacture, use, and sale of the Invention.

1.5.    Licensee is a "small business concern" as defined at Section 2 of Public
        Law 85-536 (15 U.S.C. 632).

Therefore the parties agree as follows:

                                 2. DEFINITIONS

2.1.    "Affiliate" means any legal entity that is controlled by Licensee. For
        the purposes of this definition, the term "control" means (i) beneficial
        ownership of at least fifty percent (50%) of the voting securities of a
        corporation or other entity with voting securities or (ii) a fifty
        percent (50%) or greater interest in the net assets or profits of a
        partnership or other entity without voting securities.

2.2.    "Broader Field" means the synthesis, production or modification of
        sugars and glycoconjugates in or on biological molecules for research,
        development and commercialization of human therapeutic applications.

2.3.    "Effective Date" means the date of execution by the last signing party.

2.4.    "Field Election Date" means the second anniversary of the Effective
        Date.

                                     1 of 25
<Page>

                                                                       L-03-1370

2.5.    "Field of Use" means the Broader Field for two years from the Effective
        Date, and thereafter means the Specific Applications Field; provided,
        however, if Licensee extends its rights in accordance with paragraph
        3.3, "Field of Use" shall mean the Broader Field for the life of this
        Agreement. In either case, the Field of Use specifically excludes
        application of Licensed Patents to sale of reagents for life sciences
        research purposes (the "Excluded Field"). Licensee acknowledges that the
        Invention is licensed to a third party in that Excluded Field, and that
        the Field of Use shall not be interpreted to include any part of the
        Excluded Field.

2.6.    "Highly Inflationary Currency" means the currency of any economy with a
        cumulative inflation rate of 100% or more over the most recent three
        calendar years, as measured by consumer price indices published by the
        International Monetary Fund (International Financial Statistics),
        Washington, D.C.

2.7.    "Licensed Patents" means the following:

        2.7.1.  US Patent Number 6,458,937, issued October 1, 2002, entitled
                Glycoconjugates and Methods, by Carolyn Bertozzi, Kevin J.
                Yarema, and Lara K. Mahal (Berkeley Lab case number IB-1222A);

        2.7.2.  US Patent Number 6,075,134, issued June 13, 2000, entitled,
                Glycoconjugates and Methods, By Carolyn Bertozzi, Kevin J.
                Yarema, and Lara K. Mahal (Berkeley Lab case number IB-1222);

        2.7.3.  US Patent Application Serial Number [**], entitled [**];

        2.7.4.  with respect to paragraphs 2.7.1 to 2.7.3, any corresponding
                foreign patent application or patent for which Licensee has met
                the requirements of paragraph 17.3;

        2.7.5.  any division, reexamination, continuation, continuation-in-part
                (excluding new matter contained and claimed in that
                continuation-in-part), or other application that is a successor
                to any of the foregoing applications; and

        2.7.6.  any patents issuing on any of the foregoing; and all renewals,
                reissues and extensions thereof.

2.8.    "Licensed Product" means any product, service or process that employs or
        is produced by the practice of any invention claimed in Licensed Patents
        or whose manufacture, use, practice, sale, offer for sale, or
        importation would constitute, but for the license Berkeley Lab grants to
        Licensee under this Agreement, an infringement of any Valid Claim in
        Licensed Patents in the country where such manufacture, use, practice,
        sale, offer for sale, or importation occurs.

2.9.    "Related Research Funding" means payments received by Licensee as
        reimbursement for research and development expenditures made or to be
        made by Licensee for an invention claimed in a Licensed Patent where
        such payments cover solely the actual costs of raw materials and labor,
        plus direct and indirect costs up to a maximum of [**]% ([**] percent)
        of the actual costs of raw materials and labor for such research.

2.10.   "Selling Price" for the purpose of computing royalties means the price
        received by Licensee, its Affiliate or its sublicensee for the sale of
        the Licensed Product in an arms-

                                     2 of 25
<Page>

                                                                       L-03-1370

        length transaction, less the following: (a) allowances and adjustments
        actually credited or allowed to customers; (b) trade, quantity, cash and
        prompt payment discounts actually allowed and taken; (c) taxes levied on
        and/or other governmental charges imposed as to production, sales,
        transportation, delivery or use and paid or collected by or on behalf of
        Licensee; (d) costs of insurance, packing, and transportation from the
        place of manufacture to the customer's premises or point of
        installation; provided, however, that the costs described in clauses (c)
        and (d) may only be deducted from the Selling Price if, and to the
        extent that, they are separately identified in invoices. When a Licensed
        Product is not sold, but is otherwise disposed of, the Selling Price of
        that Licensed Product for the purposes of computing royalties is the
        selling price at which products of similar kind and quality, sold in
        similar quantities, are currently being offered for sale in arms-length
        transactions by Licensee. When such products are not currently being
        offered for sale by Licensee, the Selling Price of a Licensed Product
        otherwise disposed of, for the purpose of computing royalties, is the
        average selling price at which products of similar kind and quality,
        sold in similar quantities, are then currently being offered for sale by
        other manufacturers. When such products are not currently sold or
        offered for sale by Licensee or others, then the Selling Price, for the
        purpose of computing royalties, shall be negotiated by the parties in
        good faith based on the fair market value of the Licensed Product. Sales
        or other dispositions of Licensed Products between or among Licensee and
        any of its Affiliates or sublicensees for the purpose of subsequent
        resale to third parties ("Customers") shall not be included in the
        calculation of the Selling Price.

2.11.   "Specific Applications Field" means the synthesis, production or
        modification of sugars and glycoconjugates in or on biological molecules
        for research, development and commercialization of human therapeutic
        applications solely within the three specific therapeutic applications
        that are negotiated by the parties in accordance with paragraph 3.4.

2.12.   "Valid Claim" means a claim of any (1) issued patent in any country that
        (i) has not expired; (ii) Berkeley Lab has not disclaimed; (iii) has not
        been cancelled or superseded without reinstatement; and (iv) has not
        been revoked, held invalid, or otherwise declared unenforceable or not
        allowable by a governmental tribunal or patent authority of competent
        jurisdiction over such claim in such country from which no further
        appeal has or may be taken or (2) any United States patent application
        that has not been pending for more than five years or (3) any foreign
        patent application that has not been pending for more than seven years.

                                3. LICENSE GRANT

3.1.    Subject to the limitations set forth in this Agreement, Berkeley Lab
        grants to Licensee a nontransferable, limited (by the terms of
        paragraphs 3.5 and 3.6), exclusive, worldwide, royalty-bearing license,
        under Licensed Patents, only in the Field of Use, to make and have made,
        use and have used, offer and have offered for sale, sell and have sold,
        and import and have imported Licensed Products.

3.2.    Licensee's rights from the Effective Date until the Field Election Date
        are solely within the Broader Field.

                                     3 of 25
<Page>

                                                                       L-03-1370

3.3.    Licensee may extend its rights to the Broader Field for the remainder of
        the term of this Agreement if it satisfies the following conditions by
        the Field Election Date: (1) reasonably demonstrates to Berkeley Lab
        that it has achieved the diligence milestones listed in Exhibit A; and
        (2) agrees to pay the election fee of $[**], which accrues on the Field
        Election Date, and pays the first installment in the amount of $[**] by
        the Field Election Date. The remaining two installments of $[**] are
        payable six months after the Field Election Date and twelve months after
        the Field Election Date, respectively. The election fee is
        non-refundable and is not an advance against royalties.

3.4.    If Licensee does not meet the requirements of paragraph 3.3, the Field
        of Use shall be narrowed as of the Field Election Date to cover three
        specific therapeutic applications. Licensee shall select the three
        specific applications from the list on Exhibit B, and shall send written
        notice of its selection to Berkeley Lab on or before the Field Election
        Date. The parties shall promptly negotiate in good faith to arrive,
        within 45 days of the Field Election Date, at mutually agreed on written
        definitions of the three selected therapeutic fields. Such definitions
        shall delineate with better specificity the applications described on
        Exhibit B and, so as to enable separate exclusive licensing, be
        sufficiently detailed as to be distinct from the non-elected therapeutic
        fields described on Exhibit B and other fields of use. Thereafter, the
        Field of Use will be the Specific Applications Field.

3.5.    Any license under this Agreement is subject to the following: (a) DOE's
        non-exclusive, royalty-free license for federal government purposes
        only, and (b) DOE's option to grant licenses either if reasonable steps
        to commercialize the Invention are not carried out or in order to meet
        federal regulations.

3.6.    Berkeley Lab expressly reserves the right to make and use the Invention
        and associated technology, and to allow other educational and non-profit
        institutions to do so, for noncommercial research and educational
        purposes. Without limiting the foregoing, nothing in this Agreement may
        be deemed to limit the right of Berkeley Lab to publish any technical
        data resulting from any research performed by Berkeley Lab relating to
        the Invention.

                              4. INFORMATION RIGHTS

4.1.    Unless it is legally prohibited from doing so by statute or regulation
        or contractual agreement with a research sponsor, Berkeley Lab upon
        Licensee's reasonable request shall disclose to Licensee any of its
        then-existing research data, clinical data, technical information and
        other information that is necessary or useful in connection with the
        manufacture, use or sale of any Licensed Product or the effective
        exercise or use of the Licensed Patents and that is reasonably
        accessible to the Berkeley Lab Technology Transfer Department. Licensee
        shall have the non-exclusive, worldwide, no-cost right to use all such
        information.

4.2.    Berkeley Lab shall notify Licensee of any future Berkeley-[**]
        Inventions (as defined below) within a reasonable period of time after
        any such invention is reported to the Berkeley Lab Technology Transfer
        Department, and in any case before Berkeley Lab enters into negotiations
        to license rights to such inventions to third parties. Licensee

                                     4 of 25
<Page>

                                                                       L-03-1370

        acknowledges that this notification right does NOT require Berkeley Lab
        to license to Licensee any rights to ANY future inventions. For the
        purposes of this paragraph 4.2, "Berkeley-[**] Invention" means any
        patentable invention (or group of inventions so linked as to form a
        single general inventive concept), which (1) may be licensed to third
        parties by the Ernest Orlando Lawrence Berkeley National Laboratory,
        acting on behalf of The Regents of the University of California; and (2)
        was invented by [**], either alone or with others.

                                 5. SUBLICENSING

5.1.    Berkeley Lab also grants to Licensee the right to issue fee-bearing
        (only to the extent specified in paragraphs 7.1 and 7.3) sublicenses
        only in the Field of Use to make and have made, use and have used, offer
        and have offered for sale, sell and have sold, and import and have
        imported Licensed Products, so long as Licensee has current exclusive
        rights in its Field of Use. Licensee may only grant sublicenses that are
        no greater than the Field of Use to which Licensee is entitled. By way
        of illustration, if Licensee grants a sublicense before the Field
        Election Date, and Licensee does not thereafter extend its rights to the
        Broader Field in accordance with paragraph 3.3, then the sublicensee's
        rights after the Field Election Date can be no greater than the Specific
        Applications Field.

5.2.    Licensee shall incorporate terms into any sublicense Licensee grants
        that are sufficient to enable Licensee to comply with this Agreement and
        be consistent with all the rights and obligations due Berkeley Lab and
        the United States Government under this Agreement, including, without
        limitation, the license reserved by the United States Government.

5.3.    Licensee shall provide Berkeley Lab with a copy of each sublicense
        agreement executed under this Agreement. Licensee shall have the right
        to redact terms from the sublicense agreement that are irrelevant to
        this Agreement so long as it is apparent from the document furnished to
        Berkeley Lab that the redactions are irrelevant to this Agreement.

5.4.    If this Agreement terminates for any reason, each sublicense granted by
        the Licensee in accordance with this Agreement shall remain in effect
        subject to the terms of such sublicense and the terms of this Agreement.
        Licensee shall assign each sublicense and Berkeley Lab shall assume it.
        Notwithstanding the foregoing, Berkeley Lab shall not be obligated to
        assume any sublicense that: (1) is in a state of breach as yet uncured
        by the sublicensee or (2) conflicts with state or federal law or
        Berkeley Lab's contract with DOE. Berkeley Lab shall in no event be
        bound by any duties and obligations beyond those duties and obligations
        assumed by Berkeley Lab in this Agreement and shall have all rights
        against such sublicensee as provided with respect to Licensee in this
        Agreement.

                              6. LICENSE ISSUE FEE

6.1.    Licensee shall pay Berkeley Lab a license issue fee of $40,000 (the
        "License Issue Fee"). This License Issue Fee accrues on the Effective
        Date, and Licensee shall pay this License Issue Fee as follows:
        $20,000 within 5 days of the Effective Date, $10,000 by
        February 15, 2003, and $10,000 by August 15, 2003.

                                     5 of 25
<Page>

                                                                       L-03-1370

6.2.    This License Issue Fee is non-refundable and is not an advance against
        royalties.

                            7. ROYALTIES AND PAYMENTS

7.1.    Licensee shall pay to Berkeley Lab an earned royalty of the Selling
        Price of each Licensed Product that Licensee, its Affiliate(s) or
        sublicensee(s) sells as follows, based on cumulative sales of all
        Licensed Products by Licensee, its Affiliate(s) and its sublicensees
        over the lifetime of this Agreement.

        7.1.1.  [**]% of Selling Price for cumulative sales of Licensed Products
                less than $[**];

        7.1.2.  [**]% of Selling Price for cumulative sales of Licensed Products
                between $[**] and $[**]; and

        7.1.3.  [**]% of Selling Price for cumulative sales of Licensed Products
                greater than $[**].

7.2.    Under this Agreement a Licensed Product is considered as sold when
        invoiced, or if not invoiced, when delivered to a third party Customer.
        But when the last patent covering a Licensed Product expires or when the
        license terminates, any shipment made on or before the day of that
        expiration or termination that has not been billed out before is
        considered as sold (and therefore subject to royalty). Berkeley Lab
        shall credit royalties that Licensee pays on a Licensed Product that the
        Customer does not accept or that the Customer returns.

7.3.    In addition to the payments made under paragraph 7.1, for each
        sublicense, Licensee shall pay Berkeley Lab the following:

        7.3.1.  [**]% of the up-front issue fee (excluding Related Research
                Funding), if any, that it receives from a sublicensee for any
                sublicense of the Licensed Patents;

        7.3.2.  [**]% of the annual maintenance fees (excluding Related Research
                Funding), if any, that it receives from a sublicensee for
                sublicense of the Licensed Patents; and

        7.3.3.  [**]% of milestone fees (excluding Related Research Funding), if
                any, paid to Licensee by a sublicensee; provided that
                achievement of such milestone, absent the license or sublicense,
                would infringe a Valid Claim of the Licensed Patents.

7.4.    Licensee shall pay to Berkeley Lab by August 31 of each year the
        difference between the earned royalties for that calendar year Licensee
        has already paid to Berkeley Lab (pursuant to paragraph 7.1) and the
        minimum annual royalty set forth in the applicable schedule below.
        Berkeley Lab shall credit that minimum annual royalty paid against the
        earned royalty due and owing for the calendar year for which Licensee
        made the minimum payment.

        7.4.1.  If Licensee does not extend its rights to the Broader Field
                beyond the Field Election Date (i.e., Licensee has rights solely
                in the Specific Application Field following the Field Election
                Date), then the minimum annual royalty is as follows:

                                     6 of 25
<Page>

                                                                       L-03-1370

<Table>
<Caption>
                     Calendar Year                               Minimum Annual Royalty
                -----------------------------------------------  ----------------------
                <S>                                                      <C>
                2002                                                     $ [**]
                2003                                                     $ [**]
                2004                                                     $ [**]
                2005                                                     $ [**]
                2006                                                     $ [**]
                2007                                                     $ [**]
                2008                                                     $ [**]
                2009 and each year thereafter                            $ [**]
</Table>

        7.4.2.  If Licensee elects to extend its rights to the Broader Field
                beyond the Field Election Date in accordance with paragraph 3.3,
                then minimum annual royalty is as follows:

<Table>
<Caption>
                     Calendar Year                               Minimum Annual Royalty
                -----------------------------------------------  ----------------------
                <S>                                                      <C>
                2002                                                     $ [**]
                2003                                                     $ [**]
                2004                                                     $ [**]
                2005                                                     $ [**]
                2006                                                     $ [**]
                2007                                                     $ [**]
                2008                                                     $ [**]
                2009 and each year thereafter                            $ [**]
</Table>

7.5.    Licensee shall send payment for royalties accruing to Berkeley Lab
        quarterly together with its royalty report under paragraph 9.3.

7.6.    Licensee shall make checks payable to "The Regents of the University of
        California (Berkeley Lab/L-03-1370)." Licensee shall pay Berkeley Lab
        only in United States dollars. If a Licensed Product is sold for
        currency other than United States dollars (not including Highly
        Inflationary Currency), Licensee shall first determine the earned
        royalties in the foreign currency of the country in which the Licensed
        Product was sold and then convert them into equivalent United States
        dollars at the closing exchange rate published by THE WALL STREET
        JOURNAL on the last business day of the reporting period. If a Licensed
        Product is sold for a Highly Inflationary Currency, Licensee shall
        convert the sales subject to royalties into equivalent United States
        funds using the closing exchange rates in effect on the date of
        invoicing (or if no invoicing, of delivery) as published by THE WALL
        STREET JOURNAL. Licensee shall quote the exchange rate in the
        Continental method (local currency per U.S. dollar).

7.7.    Licensee may not reduce royalties payable by any taxes, fees, or other
        charges imposed on the remittance of royalty income. Licensee is also
        responsible for all bank transfer charges.

7.8.    If Licensee cannot promptly remit any royalties for sales in any country
        where a Licensed Product is sold because of legal restrictions, upon
        notice to Berkeley Lab, Licensee may deposit in United States funds
        royalties due Berkeley Lab to Berkeley Lab's account in a bank or other
        depository in that country. If Licensee is not permitted to deposit
        those

                                     7 of 25
<Page>

                                                                       L-03-1370

        payments in U.S. funds under the laws of that country, Licensee may
        deposit those payments in the local currency to Berkeley Lab's account
        in a bank or other depository in that country.

7.9.    If a court of competent jurisdiction and last resort holds invalid any
        patent or any of the patent claims within a Licensed Patent in a final
        decision from which no appeal has or can be taken, Licensee's obligation
        to pay royalties based on that patent or claim will cease as of the date
        of that final decision. Licensee, however, shall pay any royalties that
        accrued before that decision or that are based on another patent or
        claim not involved in that decision.

7.10.   Licensee has no duty to pay Berkeley Lab royalties under this Agreement
        on a Licensed Product Licensee sells to the United States Government
        including any United States Government agency. Licensee shall reduce the
        amount charged for a Licensed Product sold to the United States
        Government by an amount equal to the royalty otherwise due Berkeley Lab.

                           8. PERFORMANCE REQUIREMENTS

8.1.    Licensee shall, itself or through its Affiliates or sublicensees,
        diligently proceed with the development, manufacture and sale of
        Licensed Products and shall diligently endeavor to market them within a
        reasonable time after the Effective Date in quantities sufficient to
        meet the market demand.

8.2.    Licensee shall make commercially reasonable efforts to obtain all
        necessary governmental approvals for the manufacture, use and sale of
        Licensed Products.

8.3.    If Berkeley Lab determines that Licensee has not met any of the
        diligence milestones listed in Exhibit C, taking into account any
        amendments or extensions pursuant to paragraph 8.4, then Berkeley Lab
        may either renegotiate those milestones in accordance with paragraph
        8.4, terminate this Agreement if the breach is not cured in accordance
        with the cure periods and other conditions of paragraph 12.1, or reduce
        Licensee's limited exclusive license to a nonexclusive license in the
        Field of Use.

8.4.    Licensee and Berkeley Lab by mutual written consent may amend or extend
        the requirements of Exhibit C at the written request of Licensee in
        response to legitimate business or technical reasons.

                         9. PROGRESS AND ROYALTY REPORTS

9.1.    Beginning May 31, 2003, and semi-annually thereafter, Licensee shall
        submit to Berkeley Lab a progress report covering Licensee's activities
        related to the development and testing of all Licensed Products and the
        obtaining of the governmental approvals necessary for marketing Licensed
        Products. Licensee shall make these progress reports until the later of
        the completion of the milestones listed in Exhibit C or commercial sales
        of any Licensed Product start.

                                     8 of 25
<Page>

                                                                       L-03-1370

9.2.    The progress reports Licensee submits under paragraph 9.1 must include,
        but not be limited to, the following topics:

        9.2.1.  summary of work completed related to the requirements of
                Exhibit C;

        9.2.2.  key scientific discoveries;

        9.2.3.  summary of work in progress;

        9.2.4.  current schedule of anticipated milestones; and

        9.2.5.  market plans for introduction of Licensed Products; and

        9.2.6.  number of full-time equivalent employees or agents (FTEs)
                working on the development of Licensed Products and overall
                number of FTEs employed by Licensee.

9.3.    Upon the earlier of five years after the Effective Date or after the
        first commercial sale of a Licensed Product anywhere in the world,
        Licensee shall make quarterly royalty reports to Berkeley Lab on or
        before February 28, May 31, August 31 and November 30 of each year. Each
        royalty report must cover the most recently completed calendar quarter
        and must show for all sales (or other disposition in accordance with
        paragraph 2.9):

        9.3.1.  the Selling Price of each type of Licensed Product sold by
                Licensee;

        9.3.2.  the number of each type of Licensed Product sold;

        9.3.3.  the royalties, in U.S. dollars, payable under this Agreement on
                those sales;

        9.3.4.  the exchange rates used in calculating the royalty due;

        9.3.5.  the royalties on government sales that otherwise would have been
                due under paragraph 7.10; and

        9.3.6.  for each sublicense, if any:

                (1)   the sublicensee;

                (2)   the information set forth in paragraphs 9.3.1 to 9.3.5 for
                      that sublicensee's sales or other disposition of Licensed
                      Product.

9.4.    If no sales of Licensed Products have been made during any required
        reporting period, Licensee shall make a statement to this effect.

                              10. BOOKS AND RECORDS

10.1.   Licensee shall keep books and records accurately showing, to the extent
        sufficient to support the reports required in paragraph 9.2, work
        performed in satisfaction of the requirements of Exhibits A and C and
        all Licensed Products manufactured, used, sold,

                                     9 of 25
<Page>

                                                                       L-03-1370

        imported or otherwise disposed of under the terms of this Agreement.
        Licensee shall preserve those books and records for at least five years
        from the date of the royalty payment to which they pertain and shall
        open them to representatives or agents of Berkeley Lab, during normal
        business hours, upon at least five (5) business days prior notice,
        solely to verify any reports and payments made or compliance in other
        respects under this Agreement. Inspections shall be limited to once per
        calendar year. Licensee shall render, at Berkeley Lab's expense, all
        assistance reasonably requested by Berkeley Lab for the purposes of
        carrying out such inspections and examination of Licensee's royalty
        payments and performance. Berkeley Lab shall maintain the results of any
        audit as Confidential Information of Licensee pursuant to paragraph
        15.3.

10.2.   Berkeley Lab shall bear the fees and expenses of Berkeley Lab's
        representatives performing the examination of the books and records. But
        if the representatives discover an error in royalties of more than 5% of
        the total royalties due for any year, then Licensee shall bear the
        reasonable and actual fees and expenses of these representatives and the
        difference between the earned royalties and the reported royalties
        (which shall be subject to the provisions of Article 22 (LATE
        PAYMENTS)). Notwithstanding the foregoing, if Berkeley Lab's
        representatives performing the examination are not independent certified
        public accountants and Licensee in good faith objects to the findings of
        such representatives, Licensee shall not be liable for the fees,
        expenses, and other payments of this paragraph 10.2, unless those
        findings are confirmed by independent certified public accountants.

                            11. LIFE OF THE AGREEMENT

11.1.   Unless otherwise terminated by acts of the parties in accordance with
        the terms of this Agreement, this Agreement is in force from the
        Effective Date and expires concurrently with the expiration, abandonment
        or final adjudication of invalidity of all Licensed Patents, whichever
        is later. Upon expiration (but not earlier termination) of this
        Agreement, Licensee shall have a non-exclusive, worldwide, no-cost right
        to use any information contained or described in the Licensed Patents
        and any information acquired by Licensee pursuant to paragraph 4.1.

11.2.   Any termination of this Agreement shall not affect the rights and
        obligations set forth in the following Articles:

        Article 10    Books and Records
        Article 11    Life of the Agreement
        Article 14    Disposition of Licensed Products on Hand upon Termination
        Article 15    Use of Names and Nondisclosure of Agreement
        Article 16    Limited Warranty
        Article 21    Indemnification
        Article 27    Export Control Laws
        Article 29    Miscellaneous
11.3.   Termination does not affect in any manner any rights of Berkeley Lab or
        Licensee arising under this Agreement before the termination.

                                    10 of 25
<Page>

                                                                       L-03-1370

                         12. TERMINATION BY EITHER PARTY

12.1.   In the event of a breach of any material term of this Agreement, then
        the non-breaching party may give written notice of such default
        ("Default Notice") to the breaching party. If the breaching party fails
        to cure that default and provide the non-breaching party with reasonable
        evidence of the cure within 90 days of the Default Notice (30 days in
        the case of breach of payment obligations by Licensee), the
        non-breaching party may terminate this Agreement and the licenses
        granted by a second written notice ("Termination Notice") to the
        breaching party after expiration of such cure period, and this Agreement
        shall automatically terminate on the deemed effective date of receipt
        (under Article 23) by the breaching party of the Termination Notice.

                           13. TERMINATION BY LICENSEE

13.1.   Licensee at any time may terminate this Agreement for any reason by
        giving written notice to Berkeley Lab. Licensee's termination notice
        must indicate whether Licensee has any inventory of Licensed Products.
        Licensee's termination of this Agreement will be effective 180 days
        after its notice.

              14. DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION

14.1.   Within 45 days of termination of this Agreement for any reason, Licensee
        shall provide Berkeley Lab with a written inventory of all Licensed
        Products in process of manufacture or in stock. Licensee shall dispose
        of those Licensed Products within 120 days of termination. The sale of
        any Licensed Product within the 120 days is subject to the terms of this
        Agreement.

                 15. USE OF NAMES AND NONDISCLOSURE OBLIGATIONS

15.1.   In accordance with California Education Code Section 92000, Licensee
        shall not use in advertising, publicity or other promotional activities
        any name, trade name, trademark, or other designation of the University
        of California, nor shall Licensee so use "Ernest Orlando Lawrence
        Berkeley National Laboratory" or "Department of Energy" (including any
        contraction, abbreviation, or simulation of any of the foregoing)
        without Berkeley Lab's prior written consent.

15.2.   Neither party may disclose the terms of this Agreement to a third party
        without express written permission of the other party, except when
        required under either the California Public Records Act or other
        applicable law or court order. Notwithstanding anything to the contrary
        in this Article 15, (i) either party may disclose the existence of this
        Agreement and identity of the other party and the extent of the grant in
        Article 3 (License Grant); (b) Berkeley Lab may disclose the terms of
        this Agreement to the DOE; and (iii) Licensee may disclose the terms of
        this Agreement to any Affiliate, any sublicensee or potential
        sublicensee, or to any third party if necessary or desirable to assist
        Licensee in building its business, in each case under a written
        confidentiality agreement no less protective than the Mutual
        Nondisclosure Agreement between the parties effective as of July 12,
        2001 (the "Mutual NDA").

                                    11 of 25
<Page>

                                                                       L-03-1370

15.3.   All information Licensee is required to provide Berkeley Lab under this
        Agreement, including but not limited to information listed in paragraphs
        5.3, 9.1, and 9.3 of this Agreement, is deemed to be Confidential
        Information.

        15.3.1. Berkeley Lab will maintain the confidentiality of the
                Confidential Information, and will not use the Confidential
                Information for any purpose other than as necessary to
                administer this Agreement.

        15.3.2. The obligations of Berkeley Lab with respect to Confidential
                Information will not apply to information disclosed under this
                Agreement to the extent such information:

                15.3.2.1.   is disclosed in a proceeding to enforce Berkeley
                            Lab's rights under this Agreement;

                15.3.2.2.   is public knowledge at the time of disclosure or
                            becomes public knowledge through no wrongful act on
                            the part of Berkeley Lab;

                15.3.2.3.   is in Berkeley Lab's possession at the time of
                            disclosure;

                15.3.2.4.   is obtained by Berkeley Lab from a third party that
                            Berkeley Lab reasonably believes is not bound by
                            confidentiality obligations to Licensee;

                15.3.2.5.   is independently developed by Berkeley Lab without
                            reference to or reliance upon the information as can
                            be documented by written records; or

                15.3.2.6.   is required to be disclosed by Berkeley Lab to
                            comply with applicable laws or governmental
                            regulations, PROVIDED THAT the Berkeley Lab provides
                            prior written notice of such disclosure to the
                            Licensee and takes reasonable and lawful actions to
                            avoid and/or minimize the extent of such disclosure.

15.4.   The provisions of this Article 15 relating to confidentiality shall be
        in force and effect until 5 years following the termination of this
        Agreement.

                              16. LIMITED WARRANTY

16.1.   Berkeley Lab warrants to Licensee that it (a) is the sole owner of the
        Licensed Patents and the Invention, and (b) has the lawful right to
        grant the licenses granted herein. In addition to the notices and
        disclaimers in this Article 16 (LIMITED WARRANTY), Licensee hereby
        agrees and acknowledges that Berkeley Lab (i) has no responsibility or
        obligation to conduct any prior art or infringement search with respect
        to the Patent Rights; and (ii) Berkeley Lab makes no representation or
        warranty, and assumes no liability, with respect to the validity or
        non-infringement of the Patent Rights. In light of the foregoing, as of
        the Effective Date of this Agreement, the Licensing Manager in Berkeley
        Lab's Technology Transfer Department, who is responsible for the
        negotiation of this Agreement, is not aware

                                    12 of 25
<Page>

                                                                       L-03-1370

        of any third party intellectual property for which the practice of the
        Licensed Patents or the Invention would be an infringing act.

16.2.   This license and the associated Invention are provided WITHOUT WARRANTY
        OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
        WARRANTY, EXPRESS OR IMPLIED. BERKELEY LAB MAKES NO REPRESENTATION OR
        WARRANTY THAT LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT OR OTHER
        PROPRIETARY RIGHT.

16.3.   IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
        CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE
        OF THE INVENTION OR LICENSED PRODUCTS, EVEN IF SUCH PARTY HAS BEEN
        ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

16.4.   Nothing in this Agreement may be construed as:

        16.4.1. a warranty or representation by Berkeley Lab as to the validity
                or scope of any of Berkeley Lab's rights in Licensed Patents;

        16.4.2. a warranty or representation that anything made, used, sold or
                otherwise disposed of under any license granted in this
                Agreement is or will be free from infringement of any patents
                other than Licensed Patents;

        16.4.3. an obligation to bring or prosecute actions or suits against
                third parties for patent infringement, except as specifically
                provided for in Article 18 (Patent Infringement); or

        16.4.4. a grant by implication, estoppel or otherwise of any license or
                rights under any patents of Berkeley Lab other than Licensed
                Patents, regardless of whether such patents are dominant or
                subordinate to Licensed Patents;

        16.4.5. an obligation to furnish any know-how not provided in Licensed
                Patents (except for information as provided in paragraph 4.1).

                        17. PATENTING AND FOREIGN RIGHTS

17.1.   Berkeley Lab shall prepare, file, prosecute and maintain patent
        applications and patents relating to inventions included in the Licensed
        Patents using patent counsel of its choice, and shall consult and
        cooperate with Licensee in connection therewith. Berkeley Lab shall copy
        Licensee promptly on all U.S.P.T.O. and foreign patent office actions so
        that Licensee shall be informed of the continuing prosecution.
        Notwithstanding the foregoing, Berkeley Lab may take any action useful
        or necessary to obtain and preserve its patent rights in Licensed
        Patents. Berkeley Lab shall use all reasonable efforts to amend any
        patent application to include claims and/or legal arguments reasonably
        requested by Licensee to protect the Licensed Products Licensee
        contemplates selling. To the extent such information is not available to
        the public, Licensee shall keep confidential documents from patent
        offices and patent related filings and associated drafts.

                                    13 of 25
<Page>

                                                                       L-03-1370

17.2.   Licensee agrees to reimburse Berkeley Lab for Berkeley Lab's
        out-of-pocket patent preparation, filing, prosecution and maintenance
        costs. Such reimbursement includes costs of $[**] incurred through June
        14, 2002, and other costs not to exceed $[**] incurred prior to the
        Effective Date. Berkeley Lab shall provide Licensee with documentation
        of patenting costs incurred when invoicing Licensee for those costs.
        Licensee will reimburse Berkeley Lab within 30 days of invoicing.
        Licensee's obligation to reimburse patent costs continues for so long as
        this Agreement remains in effect, provided, however, that Licensee may
        terminate its obligations under this Agreement with respect to any given
        patent application or patent upon three months written notice to
        Berkeley Lab. Berkeley Lab shall use reasonable efforts to curtail
        patent costs when such a notice is received from Licensee. After such
        notice or when this Agreement terminates, Berkeley Lab may continue
        prosecution and/or maintenance of those application(s) or patent(s) at
        its sole discretion and expense; provided, however, that Licensee will
        have no further license or other right to them.

17.3.   Licensee may request that Berkeley Lab seek patent protection on the
        Licensed Patents in foreign countries if available. Berkeley Lab has no
        obligation to take action to file foreign patent applications unless
        Licensee provides written notice to Berkeley Lab at least six weeks
        before any applicable bar and that notice states which countries,
        regions or Patent Cooperation Treaty filing Licensee desires. If
        Licensee timely provides such notice, then Berkeley Lab shall timely
        make such foreign filings. The absence of the required notice from
        Licensee to Berkeley Lab acts as an election not to secure foreign
        rights.

17.4.   Berkeley Lab may file patent applications at its own expense in any
        country in which Licensee has not elected to secure patent rights. Those
        applications and resultant patents shall not be subject to this
        Agreement.

17.5.   If Berkeley Lab fails to prepare, file, prosecute or maintain patent
        applications or patents described in paragraphs 17.1 or 17.3, Licensee
        shall have the right, upon prior written notice to Berkeley Lab, to
        prepare, file, prosecute or maintain such patent applications or
        patents, at Licensee's expense, in the name of Berkeley Lab.

17.6.   Licensee shall promptly notify Berkeley Lab of any change in its status
        as a small business concern and of the first sublicense granted to an
        entity that does not qualify as a small business concern. A "small
        business concern" as used in this paragraph is as defined by the U.S.
        Patent and Trademark Office; currently, that is a company whose number
        of employees, including affiliates, does not exceed 500 persons (13
        C.F.R. 121.802).

                             18. PATENT INFRINGEMENT

18.1.   If Licensee learns of the substantial infringement of any of Licensed
        Patents, Licensee shall so inform Berkeley Lab in writing and shall
        provide Berkeley Lab with reasonable evidence of the infringement.
        During the period and in a jurisdiction where Licensee has exclusive
        rights under this Agreement, neither party may notify a third party of
        the infringement of any of Licensed Patents without first obtaining
        written consent of the other party, which consent shall not be
        unreasonably denied. Subject to paragraph 18.2, both

                                    14 of 25
<Page>

                                                                       L-03-1370

        parties shall use their reasonable efforts in cooperation with each
        other to resolve such infringement without litigation.

18.2.   Licensee may request that Berkeley Lab take legal action against the
        infringement of Licensed Patents in the Field of Use in which Licensee
        has exclusive rights under this Agreement. Licensee shall make that
        request in writing and include reasonable evidence of the infringement
        and damages to Licensee. If the infringing activity has not been abated
        within 90 days of that request, Berkeley Lab may elect to: (a) commence
        suit on its own account; or (b) refuse to participate in the suit.
        Berkeley Lab shall give written notice of its election to Licensee by
        the end of the 100th day after receiving notice of the request from
        Licensee. Licensee may thereafter bring suit for patent infringement
        only if Berkeley Lab elects not to commence suit and if the infringement
        occurred during the period and in a jurisdiction where Licensee has
        exclusive rights under this Agreement. If Berkeley Lab brings suit in
        accordance with this paragraph, Licensee may thereafter join such suit,
        at its own expense, and contribute up to fifty percent of the costs of
        such suit. If Licensee elects to bring suit in accordance with this
        paragraph, Berkeley Lab may thereafter join such suit, at its own
        expense, and contribute up to fifty percent of the costs of such suit.
        Subject to this paragraph 18.2, if required by law, each party shall
        permit any action under this paragraph to be brought in its name,
        including being joined as a nominal party-plaintiff, provided that the
        other party shall hold such party harmless from, and indemnify the such
        party against, any costs, expenses or liability that such party incurs
        in connection with such action.

18.3.   Such legal action as is decided upon must be at the expense of the party
        on account of whom suit is brought and all consequent recoveries belong
        to that party. But if Berkeley Lab and Licensee jointly bring legal
        action and fully participate in it, the parties must jointly share the
        expense and all recoveries shall be shared in proportion to the share of
        expense each party pays.

18.4.   Each party shall cooperate with the other in litigation proceedings
        instituted under this Agreement but at the expense of the party on
        account of whom suit is brought. The party bringing the suit will
        control that litigation, including the settlement thereof, subject to
        the right of Berkeley Lab to be represented by counsel of its choice in
        any suit brought by Licensee, it being understood that Licensee will
        still control litigation brought by it.

                                   19. WAIVER

19.1.   The waiver of any breach of any term of this Agreement does not waive
        any other breach of that or any other term.

                                    15 of 25
<Page>

                                                                       L-03-1370

                                 20. ASSIGNMENT

20.1.   This Agreement is binding upon and shall inure to the benefit of (a)
        Berkeley Lab, its successors and assigns and (b) Licensee, its
        successors and permitted assigns. This Agreement is personal to the
        Licensee. Any attempt by Licensee to assign this Agreement is void
        unless Licensee obtains the prior written consent of Berkeley Lab;
        Berkeley Lab shall not unreasonably withhold that consent. Berkeley Lab
        acknowledges that it shall not be reasonable for Berkeley Lab to
        withhold its consent if the third party to whom Licensee desires to
        assign this Agreement has the expertise and financial ability to exploit
        the licenses granted under this Agreement (i.e., is not an entity with
        limited assets and personnel). Notwithstanding the preceding sentence,
        after Licensee has achieved the milestone described in Section 5 of
        Schedule C, Licensee may assign this Agreement, upon written notice to
        Berkeley Lab and without Berkeley Lab's consent, in conjunction with the
        sale or transfer of all or substantially all of its assets related to
        the commercialization of the Licensed Patents, or pursuant to a merger
        or consolidation, to or into an entity which has agreed in writing to be
        bound by all the terms and conditions of this Agreement.

                               21. INDEMNIFICATION

21.1.   Licensee agrees to indemnify, hold harmless and defend Berkeley Lab and
        the U.S. Government and their officers, employees, and agents; the
        sponsors of the research that led to the Invention; and the inventors of
        the patents and patent applications in Licensed Patents and their
        employers against any and all claims, suits, losses, damage, costs,
        fees, and expenses ("Claims") resulting from or arising out of
        Licensee's or its Affiliates' exercise of this license or its
        sublicensees' exercise of any sublicense, except to any indemnified
        party to the extent that Claims result from the gross negligence or
        willful misconduct of Berkeley Lab or its officers, employees, or
        agents. Licensee shall pay all costs incurred by Berkeley Lab in
        successfully enforcing this indemnification, including reasonable
        attorney fees. The indemnity set forth herein shall apply only if
        Licensee shall have been informed in writing as soon and as completely
        as practical by Berkeley Lab and/or the Government of the action
        alleging such Claim, the indemnified parties cooperate fully with
        Licensee in the defense of any such Claim, and Licensee shall have been
        given an opportunity, to the maximum extent afforded by applicable laws,
        rules, or regulations, to control its defense and settlement. Neither
        Licensee nor any indemnified party shall agree to any settlement of such
        Claim that does not include a complete release of the other party(-ies)
        from all liability with respect thereto or that imposes any liability,
        obligation or restriction on such other party(-ies) without such other
        party(-ies) consent unless required by final decree of a court of
        competent jurisdiction. Licensee may participate in the defense of any
        claim through its own counsel, and at its own expense.

21.2.   Licensee, at its sole expense, shall insure its activities related to
        this Agreement and obtain and keep in force Comprehensive or Commercial
        Form General Liability Insurance (contractual liability and products
        liability included) with limits as follows:

<Table>
        <S>                                                          <C>
        21.2.1. Each Occurrence                                      $ 4,000,000

        21.2.2. Products/Completed Operations Aggregate              $ 5,000,000
</Table>

                                    16 of 25
<Page>

                                                                       L-03-1370

<Table>
        <S>                                                          <C>
        21.2.3. Personal and Advertising Injury                      $ 4,000,000

        21.2.4. General Aggregate (commercial form only)             $ 4,000,000
</Table>

21.3.   The coverages and limits referred to in this Article 21 do not in any
        way limit the liability of Licensee. Licensee shall furnish Berkeley Lab
        with certificates of insurance, including renewals, evidencing
        compliance with all requirements at least 30 days prior to the first
        commercial sale, clinical use, practice or distribution of a Licensed
        Product.

        21.3.1. If such insurance is written on a claims-made form, coverage
                shall provide for a retroactive date of placement on or before
                the Effective Date.

        21.3.2. Licensee shall maintain the general liability insurance
                specified during: (a) the period that the Licensed Product is
                being commercially distributed or sold by Licensee or by a
                sublicensee or agent of Licensee, and (b) a reasonable period
                thereafter, but in no event less than five years.

21.4.   The insurance coverage of paragraph 21.2 must:

        21.4.1. Provide for 30-day advance written notice to Berkeley Lab of
                cancellation or of any modification.

        21.4.2. Indicate that DOE, "The Regents of the University of California"
                and its officers, employees, students, agents, are endorsed as
                additional insureds.

        21.4.3. Include a provision that the coverages are primary and do not
                participate with, nor are excess over, any valid and collectible
                insurance or program of self-insurance carried or maintained by
                Berkeley Lab.

                                22. LATE PAYMENTS

22.1.   If Licensee does not make a payment to Berkeley Lab when due, Licensee
        shall pay to Berkeley Lab such reasonable administrative fees and the
        lesser of 10% simple interest per annum or the maximum permitted by law.

                                   23. NOTICES

23.1.   Any payment, notice or other communication this Agreement requires or
        permits either party to give must be in writing to the appropriate
        address given below or to such other address as one party designates by
        written notice to the other party. The parties deem payment, notice or
        other communication to have been properly given and to be effective (a)
        on the date of delivery if delivered in person; (b) on the fourth day
        after mailing if mailed by first-class mail, postage paid; (c) on the
        second day after delivery to an overnight courier service such as
        Federal Express, if sent by such a service; or (d) upon confirmed
        transmission by telecopier. The parties' addresses are as follows:

                                    17 of 25
<Page>

                                                                       L-03-1370

                For Berkeley Lab:

                Lawrence Berkeley National Laboratory
                Technology Transfer Department
                Mailstop 90-1070
                One Cyclotron Road
                Berkeley, California 94720
                Attention: Licensing Manager
                Fax: 510/486-6457
                Telephone: 510/486-6467

                For Licensee:

                Momenta Pharmaceuticals, Inc.
                43 Moulton Street
                Cambridge, MA 02138
                Attention: Vice President Licensing and Business Development
                Fax: 617/491-9701
                Telephone: 617/491-9700

                              24. U.S. MANUFACTURE

24.1.   To the extent required by law, Licensee shall have Licensed Products
        produced for sale in the United States manufactured substantially in the
        United States so long as Licensee has current exclusive rights in the
        Field of Use.

                               25. PATENT MARKING

25.1.   Licensee shall mark all Licensed Products made, used or sold under this
        Agreement, or their containers, in accordance with the applicable patent
        marking laws.

                     26. GOVERNMENT APPROVAL OR REGISTRATION

26.1.   If the law of any nation requires that any governmental agency either
        approve or register this Agreement or any associated transaction,
        Licensee shall assume all legal obligation to do so. Licensee shall
        notify Berkeley Lab if it becomes aware that this Agreement is subject
        to a U.S. or foreign government reporting or approval requirement.
        Licensee shall make all necessary filings and pay all costs, including
        fees, penalties, and all other costs associated with such reporting or
        approval process.

                             27. EXPORT CONTROL LAWS

27.1.   Licensee shall observe all applicable United States and foreign laws and
        regulations with respect to the transfer of Licensed Products and
        related technical data, including, without limitation, the International
        Traffic in Arms Regulations (ITAR) and the Export Administration
        Regulations.

                                    18 of 25
<Page>

                                                                       L-03-1370

                                28. FORCE MAJEURE

28.1.   If a party's performance required under this Agreement is rendered
        impossible or unfeasible due to any catastrophes or other major events
        beyond its reasonable control, including, without limitation, the
        following, the parties are excused from performance: war, riot, and
        insurrection; laws, proclamations, edicts, ordinances or regulations;
        strikes, lockouts or other serious labor disputes; and floods, fires,
        explosions, or other natural disasters. When such events abate, the
        parties' respective obligations under this Agreement must resume.

                                29. MISCELLANEOUS

29.1.   The headings of the several sections are inserted for convenience of
        reference only and are not intended to be a part of or to affect the
        meaning or interpretation of this Agreement.

29.2.   This Agreement is not binding upon the parties until it is signed below
        on behalf of each party.

29.3.   No amendment or modification hereof shall be valid or binding upon the
        parties unless made in writing and signed on behalf of each party.

29.4.   This Agreement and the Mutual NDA, which is incorporated herein by
        reference, embody the entire and final understanding of the parties on
        this subject matter. They supersede any previous representations,
        agreements, or understandings, whether oral or written, relating to
        their subject matter.

29.5.   If a court of competent jurisdiction holds any provision of this
        Agreement invalid, illegal or unenforceable in any respect, this
        Agreement must be construed as if that invalid or illegal or
        unenforceable provision is severed from the Agreement, provided,
        however, that the parties shall negotiate in good faith substitute
        enforceable provisions that most nearly effect the parties' intent in
        entering into this Agreement.

29.6.   This Agreement must be interpreted under the laws of the state of
        California, without giving effect to any choice of law rules that would
        result in the application of laws of any jurisdiction other than those
        of the state of California, except that questions affecting the
        construction and effect of any patent shall be determined by the law of
        the country in which the patent is granted.

                                    19 of 25
<Page>

                                                                       L-03-1370

Berkeley Lab and Licensee execute this Agreement in duplicate originals through
their duly authorized respective officers in one or more counterparts, that
taken together, are but one instrument.

THE REGENTS OF THE UNIVERSITY             MOMENTA PHARMACEUTICALS, INC.
OF CALIFORNIA, THROUGH THE
ERNEST ORLANDO LAWRENCE
BERKELEY NATIONAL LABORATORY

By:     /s/ Piermaria Oddone              By:      /s/ Susan K. Whoriskey
        -----------------------------              -----------------------------
             (Signature)                                 (Signature)

By      Piermaria Oddone, Ph.D.           By       Susan K. Whoriskey, Ph.D.

Title   Deputy Laboratory Director        Title    Vice President, Licensing and
                                                   Business Development

Date    11/6/02
                                          Date     11-20-02

Approved as to form

By:     /s/ Glenn R. Woods
        -----------------------------
        GLENN R. WOODS
        LAWRENCE BERKELEY NATIONAL LABORATORY

                                    20 of 25
<Page>

                                                                       L-03-1370

                                    EXHIBIT A

                Diligence Milestones for Rights to Broader Field

1.   Licensee shall have raised from inception at least $1,000,000, in the
     aggregate, from the sale of Licensee's equity securities for its own
     account and/or from funding from corporate partners or sublicensees or
     otherwise.

2.   Licensee shall have hired a Vice President R&D to its senior management
     team, acquired expertise in regulatory affairs and clinical development
     and employ a staff of 25 employees, of which at least 12 have advanced
     science degrees (Ph.D. or M.D.)

3.   Licensee shall have established a preclinical and IND candidate program
     on glycosylated therapeutics using the Licensed Patents, either
     alone or in collaboration with other parties.

4.   Licensee shall have either (a) established a paying collaboration with a
     for-profit entity such as a pharmaceutical or biotechnology company in
     which Licensee reasonably expects to earn at least $500,000 during the
     course of the collaboration, or (b) as a higher value alternative for
     Licensee to such paying collaboration, developed written plan and begun
     implementation of that plan to establish by itself a glycosylated
     therapeutics program using the Licensed Patents beyond the IND stage.

                                    21 of 23
<Page>

                                                                       L-03-1370

                                    EXHIBIT B

           Therapeutic Applications within Specific Applications Field

[**]therapies

[**] therapies

[**] therapies, including [**]

[**] therapies

[**] therapies

[**] therapies [**]

[**] therapies

[**] therapies

[**] therapies

[**] therapies

[**] therapies

[**] therapeutic applications

And any other field upon which the parties may mutually agree.

                                    22 of 23
<Page>

                                                                       L-03-1370

                                    EXHIBIT C

                              Diligence Milestones

1.   Licensee shall permit an in-plant inspection by Berkeley Lab on or before
     November 2002 and thereafter permit in-plant inspections by Berkeley Lab at
     regular intervals with at least twelve (12) months between each inspection.

2.   Licensee shall have raised from inception at least $1,000,000 by May 1,
     2003 from the sale of Licensee's equity securities for its own account.

3.   In the aggregate, Licensee shall have raised from inception at least
     $4,000,000 by December 1, 2004 from the sale of Licensee's equity
     securities for its own account and from funding from corporate partners
     or sublicensees or otherwise.

4.   Licensee shall fund, or shall cause its Affiliates, sublicensees and/or
     corporate partners to fund, no less than $250,000 toward the research,
     development or commercialization of Licensed Products in each calendar year
     (pro-rated for partial years) beginning in the calendar year 2002 and
     ending with calendar year 2004.

5.   Licensee shall have advanced, or shall have caused its Affiliates or
     sublicensees to advance, by March 30, 2004, a novel, re-engineered
     glycosylated molecule Licensed Product into pre-clinical development. In
     lieu of this requirement, Licensee shall fund, or shall cause its
     Affiliates, sublicensees and/or corporate partners to fund, no less than
     $500,000 toward the research development or commercialization of
     Licensed Products in calendar year 2004.

6.   Licensee shall fund, or shall cause its Affiliates, sublicensees and/or
     corporate partners to fund, no less than $1,000,000 toward the research,
     development or commercialization of Licensed Products in each calendar year
     (pro-rated for partial years) beginning in calendar year 2005 and shall
     continue such funding until the arms-length commercial sales of a Licensed
     Product total in the aggregate at least $100,000.

                                    23 of 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]